Document:

LICENSE AGREEMENT

 Confidential 
 Exhibit 10.1 
 LICENSE AGREEMENT 
 BY AND BETWEEN 
 ANTIGENICS, INC., A MASSACHUSETTS CORPORATION 

AND 
 GLAXOSMITHKLINE BIOLOGICALS
SA 

 Confidential 
  

 LICENSE AGREEMENT 
 This License Agreement (this “Agreement”) is made effective this 6th day of July, 2006 (“Effective Date”) by and
between Antigenics, Inc., a Massachusetts corporation and wholly owned subsidiary of Antigenics, Inc., a Delaware corporation, having offices at 3 Forbes Road, Lexington, MA 02421 (“Antigenics MA”), and GlaxoSmithKline Biologicals
SA, a Belgian company, having an address at 89 rue de l’Institut, 1330 Rixensart Belgium (“GSK”) (each singularly a “Party” and collectively the “Parties”). 
 WHEREAS, Antigenics MA and GSK are parties to that certain License, Development, and Supply Agreement entered into effective September 11, 1992
between Cambridge Biotech Corporation (predecessor to Antigenics MA) and Smithkline Beecham p.l.c. (predecessor to GlaxoSmithKline plc, an Affiliate of GSK) (as amended, the “Prior Agreement”); and 
 WHEREAS, GSK has an interest in gaining certain manufacturing rights for QS-21 and restructuring its partnering arrangement with Antigenics MA;

 WHEREAS, Antigenics MA has an interest in expanding its collaborative relationship with GSK; 
 WHEREAS, GSK and Antigenics MA now desire to terminate and supercede the Prior Agreement with this Agreement and the Supply Agreement (as hereinafter
defined); 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as follows: 
 1. Definitions.

 The following terms, whether used in the singular or the plural, shall have the following meanings for purposes of this Agreement:

 1.1 “Affiliate” means any corporation, firm, partnership or other entity, which controls, is controlled by or is under
common control with a Party. For purposes of this Section 1.1, “control” means direct or indirect ownership of fifty percent (50%) or more, or such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction, of the outstanding stock or other voting rights entitled to elect directors thereof or the ability to otherwise control the management of the corporation, firm, partnership or other entity. 
 1.2 “Annual Update” means the annual update of GSK’s development and commercialization efforts including the [**] and plans of [**]
activities in each [**], [**] of [**] of QS-21 in the [**] under evaluation for each [**] in each [**], [**] and [**] dates and [**] and [**] dates with respect to each [**] in the [**], as prepared by GSK and presented to and discussed with
Antigenics MA during an annual meeting in accordance with this Agreement. 
 [**] = Portions of this exhibit have been omitted pursuant to a confidential
treatment request. An unredacted version of this exhibit has been filed separately with the Commission. 
  

 1 

 Confidential 
  

 1.3 “BLA” means a Biologics License Application or similar application (including
without limitation a New Drug Application) filed with the FDA, or any comparable filing in any non-US jurisdiction with any relevant Regulatory Authority. 
 1.4 “BMF” means Antigenics MA’s FDA biologics master file for QS-21. 
 1.5
“Business Day” means a day on which banking institutions in both Brussels, Belgium and Boston, Massachusetts are open for business. 
 1.6 “Co-exclusive Vaccine” means any prophylactic and/or therapeutic Vaccine product for the sole purpose of eliciting an immune response to one or more antigens directed to any indication listed on
Exhibit B attached hereto and incorporated herein, solely or in combination with other indications listed on Exhibit C and D attached hereto, formulated and delivered in combination with QS-21 with or without other adjuvants. For the
sake of clarity, Co-exclusive Vaccines shall specifically exclude any and all (i) formulations of QS-21 with [**] or with [**] (provided however that said exclusion shall not [**] from [**] or [**] with [**] and/or [**] by GSK), and/or
(ii) uses of QS-21 without an antigen, including without limitation, combinations where antigens are not present. 
 1.7
“Combination Vaccines” means Licensed Vaccines formulated in combination with one or more Other Vaccine Product(s) (as defined in Section 1.22 below). 
 1.8 “Commercially Reasonable Efforts” means efforts in accordance with GSK’s scientific, medical, legal and business judgment and
consistent with the efforts used by GSK for its own internal products and by similar companies in the biotechnology and pharmaceutical industries for products of similar commercial value, status and market potential under similar market conditions.

 1.9 “Confidential Information” has the meaning set forth in Article 9 hereof. 
 1.10 “Exclusive Vaccine” means any prophylactic and/or therapeutic Vaccine product for the sole purpose of eliciting an immune response
to one or more antigens directed to any indication listed on Exhibit C attached hereto and incorporated herein, solely or in combination with other indications listed on Exhibit B and D attached hereto, formulated and delivered in
combination with QS-21. For the sake of clarity, Exclusive Vaccines shall specifically exclude any and all (i) formulations of QS-21 with [**] or with [**] (provided, however that said exclusion shall not [**] from [**] or [**], [**] with [**]
and/or [**] or [**] by GSK), and/or (ii) uses of QS-21 without an antigen, including without limitation, combinations where antigens are not present. 
 1.11 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 2 

 Confidential 
  

 1.12 “First Commercial Sale” means the date of first commercial sale of a Licensed
Vaccine by GSK or its Affiliates or Third Party Sublicensees anywhere in the world. 
 1.13 “Gross Sales” has the meaning
set forth in Section 1.22 below. 
 1.14 “GSK Invention” means any invention or discovery (a) which is conceived
or reduced to practice by or on behalf of GSK, its Affiliates or Third Party Sublicensees at any time up to the [**] anniversary of the [**] hereof as a result of the practice of the Licensed Patent Rights or the use of QS-21 pursuant to this
Agreement, the Supply Agreement, and/or the Prior Agreement and (b) in so far as it is related to QS-21 and in so far as it is not related to (i) [**], (ii) [**], (iii) [**] and/or (iv) any other [**], and
(c) that would block the making, using, or selling of QS-21 in Antigenics MA’s or its Affiliates’ [**] based [**]. 
 1.15
“GSK Patent Rights” means any U.S. or foreign patent applications, provisional patent applications and patents issuing therefrom worldwide, together with any extensions, registrations, confirmations, reissues, continuations,
divisions, continuations-in-part, reexamination certificates, confirmations, registrations, revalidations, additions, substitutions, or renewals thereof and any patents anywhere in the world claiming the priority date of any of the foregoing, in
each case owned or controlled by GSK, its Affiliates, licensees or sublicensees (and for which GSK has the right to grant licenses or sublicenses hereunder) to the extent claiming, covering or directed to the subject matter of a GSK Invention.

 1.16 “Licensed Indications” means the Vaccine indications identified in Exhibits B, C, and D for which GSK has
rights with respect to Exclusive Vaccines, Co-exclusive Vaccines, or Non-exclusive Vaccines. 
 1.17 “Licensed Know-how”
means all tangible and intangible information and data owned or controlled by Antigenics MA (and for which Antigenics MA has the right to grant licenses during the Term), which are not generally known, which relate to QS-21, which are substantial
and have been identified or summarized in writing by Antigenics MA, and which are necessary for GSK to develop, make, use, sell, offer for sale and import Licensed Vaccines or to practice the Licensed Patent Rights. In no event shall Know-how
include any information or know-how of Antigenics MA related to the manufacture of QS-21, it being the understanding of the Parties that such information and know-how shall be the subject of the Supply Agreement. 
 1.18 “Licensed Patent Rights” means (i) United States Patent No.’s [**], and (ii) PCT Publication No.[**] and US Patent
Application USSN [**] ((ii), collectively, the “[**] Patents”) , together with (iii) any patents issuing from any continuations, continuations-in-part (to the extent that the claims are directed to subject matter specifically
disclosed in (i) or (ii)), divisionals, substitutions, reissues, reexaminations or extensions of the Patents, and any foreign counterparts or equivalents of the foregoing. Also included in the definition of Licensed Patent Rights are any
patents or patent applications which generically or specifically claim any improvements in so far as such improvements are [**] to [**] and in so far as such improvements are not [**] to [**](other than [**]) of Antigenics MA or its Affiliates
which are 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 3 

 Confidential 
  

 
conceived or reduced to practice by Antigenics MA, its Affiliates, licensees or sublicensees at any time up to the [**] of the Effective Date hereof, and
which are owned or controlled by Antigenics MA, its Affiliates, licensees or sublicensees and for which Antigenics MA has the right to grant licenses during the Term. For the avoidance of doubt, and notwithstanding the foregoing, the Parties agree
that Licensed Patent Rights do not include (i) patents or patent applications relating to the compounds derived by or on behalf of Antigenics MA from QS-21 designed for drug delivery instead of immune response potentiation, or (ii) patents
or patent applications relating to immunomodulation without an antigen, or (iii) patent applications claiming manufacturing processes for QS-21 it being the understanding of the Parties that the grant to GSK of a license to such patent
applications claiming manufacturing processes for QS-21 is the subject of the Supply Agreement. The current Licensed Patent Rights are listed on Exhibit I. 
 1.19 “Licensed Technology” means QS-21 and Licensed Know-how. 
 1.20 “Licensed
Vaccine(s)” means Exclusive Vaccines, Co-Exclusive Vaccines, and Non-Exclusive Vaccines. 
 1.21 “Marketing
Approval” means approval received from the FDA or any comparable approval in any non-US jurisdiction with any relevant Regulatory Authority granting the right to commercialize Licensed Vaccines (but specifically independent of pricing or
reimbursement considerations, where applicable). 
 1.22 “Net Sales” means the amount billed or invoiced on arms length
sales of Licensed Vaccines by GSK or its Affiliates or Third Party Sublicensees to Third Parties including its distributors under this Agreement (“Gross Sales”) less deductions duly documented for (i) normal and customary
trade, quantity and cash discounts and non-affiliated broker’s, distributor’s or agent’s commissions actually allowed and taken; (ii) amounts repaid or credited by reason of rejection or return or retroactive price reduction;
(iii) to the extent separately stated on purchase or sales orders, invoices, or other documents of sale, sales and excise taxes and duties levied on and/or other governmental charges made as to production, sale, importation, transportation,
delivery or use paid by or on behalf of GSK or its Affiliates or Third Party Sublicensees]; (iv) transportation costs including insurance; (v) the [**] determined as [**] of [**] and other special [**] and/or [**] and [**] with Licensed
Vaccines; (vi) any [**] to [**] on [**] provided however that [**] under [**] shall not exceed [**] of [**] and (vii) contributions and payments required by the [**] to be made pursuant to the [**], specifically with respect to any of the
[**], which [**] and [**] have been [**] on to the [**] and are [**] in the [**] of [**] and which are not [**], provided however that deductions under this subparagraph (vii) and subparagraph (v) shall not [**] of [**] in the [**]. Sales
between or among GSK and its Affiliates or Third Party Sublicensees shall be excluded from the computation of Net Sales except where the Affiliates or Third Party Sublicensees are end users, but Net Sales shall include the subsequent final sales to
Third Parties by the Affiliates or Third Party Sublicensees. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 4 

 Confidential 
  

 For the avoidance of doubt, in the event GSK gets any indirect financial interest, income or other consideration back
from the subsequent sales of GSK distributors to Third Parties, such financial interest, income or consideration shall be included as Net Sales hereunder. In addition, in the event that GSK has entered into a distribution agreement with a Third
Party in form that is in economic and business substance a sublicense relationship and not a traditional distribution relationship in such country or countries, then such distributor shall be treated as a Sublicensee for purposes of calculating
Net Sales, Sublicense Revenues, and royalties hereunder.
 If GSK or any of its Affiliates or Third Party Sublicensees makes any transfer of Licensed
Vaccines to Third Parties for consideration other than monetary value or as part of a multi-product transaction, such transfer will be considered a sale hereunder for Net Sales, accounting and royalty purposes. Net Sales for any such transfers will
be determined on a country by country basis and will be the average price of “arms length” sales of Licensed Vaccines by GSK or its Affiliates or Third Party Sublicensees in such country during the royalty reporting period in which such
transfer occurs or, if no such “arms length” sales occurred in such country during such period, during the last period in which such “arms length” sales occurred. If no “arms length” sales have occurred in a particular
country, Net Sales for any such transfer in such country will be the average price of “arms length” sales of Licensed Vaccines in all countries in the Territory by GSK, its Affiliates or Third Party Sublicensees. 
 If Licensed Vaccine(s) is (are) sold as part of a Combination Vaccine, Net Sales for purposes of determining royalties on Licensed Vaccine(s) in the Combination Vaccine
shall be calculated by [**] of the [**] (as determined in accordance with the provisions of this Section) by the [**], where [**] is the [**] of the Licensed Vaccine(s) [**] in the [**] and [**] and [**] is the [**] of the [**] in the [**] in the
[**] and [**]. 
 In the event that no such separate sales are made of the Licensed Vaccine or Other Vaccine Product(s) in such Combination Vaccine in the
relevant country during the royalty period in question, then Net Sales for purposes of determining royalties on Licensed Vaccine(s) in the Combination Vaccine shall be calculated by [**] of the [**] (as determined in accordance with the provisions
of this Section) by the [**], where [**] is the [**] of the Licensed Vaccine(s) [**] in [**] within the [**] and [**], and [**] is the [**] of the [**] in such [**] within the [**] and [**]. 
 In the event that no such separate sales are made of the Licensed Vaccines or any of the Other Licensed Vaccines in such Combination Vaccine in the relevant countries
within the same geographical region and similar economic profile during the royalty period in question, Net Sales, for the purposes of determining royalty payments royalties on Licensed Vaccine(s) in the Combination Vaccine shall be calculated as
[**] in [**] the [**] provided that in the event the Parties are [**] to [**] to [**] on [**] after [**], then [**] shall be [**] for [**] to an [**] to the [**] shall be [**]. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 5 

 Confidential 
  

 1.23 “Non-exclusive Vaccine” means any prophylactic and/or therapeutic Vaccine
product for the sole purpose of eliciting an immune response to one or more antigens directed to any indication listed on Exhibit D attached hereto and incorporated herein, solely or in combination with other indications listed on Exhibits
B and C, formulated and delivered in combination with QS-21 with or without other adjuvants. For the sake of clarity, Non-exclusive Vaccines shall specifically exclude any and all (i) formulations of QS-21 with [**] or with [**] (provided
however that said exclusion shall not [**] from [**] or [**], Non-exclusive Vaccines with [**] and/or [**] or [**] by GSK), and/or (ii) uses of QS-21 without an antigen, including without limitation, combinations where antigens are not present
and/or (iii) any [**] containing [**] (whether alone or in combination with each other) for the prevention and/or treatment of human cancers. 
 1.24 “Other Vaccine Product” means any vaccine product, other than a Licensed Vaccine, which is [**] with [**] and [**] when [**] with the [**] as [**] by [**] to [**]. 
 1.25 “QS-21” means a substantially pure saponin adjuvant isolated from crude Quillaja saponaria tree extract and referred to as
QS-21, a Stimulon® adjuvant. 
 1.26 “Regulatory Authority” means the U.S. or foreign government agency or health authority that regulates and grants recommendations
for approvals for the manufacture and sale of pharmaceutical products. 
 1.27 “Steering Committee” has the meaning set
forth in the Supply Agreement. 
 1.28 “Sublicensee” means any Affiliate or Third Party to whom GSK grants a sublicense of
any of the license rights granted to GSK hereunder pursuant to the terms and conditions of this Agreement. 
 1.29 “Sublicense
Revenue” means any [**] and [**], and/or [**] by [**] from a [**] treated as a [**] in accordance with Section 1.22 in consideration for the sublicense rights to QS-21 granted GSK under this Agreement. In the event that GSK grants a
sublicense to the rights granted by Antigenics MA hereunder in addition to a sublicense to other GSK technologies, then a [**] of any such [**] shall be [**] by [**] as [**] for the [**] to [**] under the [**] and/or[**] hereunder by [**]. GSK shall
share with Antigenics MA the relevant portions of such sublicense terms and Antigenics MA shall treat such information as Confidential Information in accordance with this Agreement. In the event of a dispute regarding such allocation, the matter
shall be resolved under Section 12.1. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 6 

 Confidential 
  

 1.30 “Supply Agreement” shall have the meaning set forth in Section 6.1 hereof.

 1.31 “Term” has the meaning set forth in Section 10.1 hereof. 
 1.32 “Territory” means the world. 
 1.33 “Third Party” means any entity other than the Parties to this Agreement or their respective Affiliates. 
 1.34 “Vaccine” means a preparation in finished form (not requiring any further processing or packaging prior to sale to the end user). 
 1.35 “Valid Claim” means a claim of an issued, unexpired patent, or a claim of a pending patent application, included within the Licensed Patent Rights, which has not been held invalid, unpatentable
or unenforceable in an unappealed or unappealable decision of a court or other governmental body of competent jurisdiction, which has not been rendered unenforceable through disclaimer or otherwise, and which has not been lost through an
interference proceeding, provided that if any pending patent application is pending for more than [**], it shall cease to be within the definition of Valid Claim unless and until it issues. 
 2. License. 
 2.1 License Grant to GSK Subject
to the terms and conditions of this Agreement, Antigenics MA hereby grants to GSK during the Term: 
 (a) an exclusive license
(even as to Antigenics MA), with the right to sublicense solely as set forth in Section 2.2 below, under the Licensed Patent Rights to use QS-21 to develop, make, have made, use, sell, offer for sale, keep and import Exclusive Vaccines within
the Territory; 
 (b) a co-exclusive license (with either Antigenics MA or a sole sublicense of Antigenics MA in each country
or group of countries), with the right to sublicense solely as set forth in Section 2.2 below, under the Licensed Patent Rights to use QS-21 to develop, make, have made, use, sell, offer for sale, keep and import Co-exclusive Vaccines within
the Territory; 
 (c) a non-exclusive license, with the right to sublicense solely as set forth in Section 2.2 below,
under the Licensed Patent Rights to use QS-21 to develop, make, have made, use, sell, offer for sale, keep and import Non-exclusive Vaccines within the Territory; 
 (d) an exclusive license (even as to Antigenics MA), with the right to sublicense solely as set forth in Section 2.2 below, under the
[**] Patents to develop, make, have made, use, sell, offer for sale, keep and import Licensed Vaccines in the Licensed Indication of cancer within the Territory; and 
 (e) a non-exclusive license, with the right to sublicense solely as set forth in Section 2.2 below, under the Licensed Technology to
use QS-21 to develop, make, have made, use, sell, offer for sale, keep and import Licensed Vaccines within the Territory. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 7 

 Confidential 
  

 Notwithstanding the foregoing, the license rights granted to GSK under subsections (a) through (e) of this
Section 2.2 expressly exclude any rights under the Licensed Patent Rights or Licensed Technology to develop, make, have made, use, sell, offer for sale, keep and import any vaccine products containing [**] (whether alone or in combination with
each other) for the prevention and/or treatment of human cancers. 
 Nothing in this Agreement shall restrict GSK’s ability to exploit its own
technology or to carry out research outside the Licensed Indications, provided however that nothing in this Agreement shall be construed as Antigenics MA granting GSK or its Affiliates or other Sublicensees
(a) any affirmative right to use the Licensed Technology or Licensed Patent Rights outside the Licensed Indications, including without limitation, combinations of Licensed Vaccines with other Vaccine Products, or (b) any right to
manufacture (or have made) QS-21 for use in the research, development or commercialization of Licensed Vaccines, it being the understanding of the Parties that the provision of such a manufacturing right is the subject of the Supply
Agreement.
 2.2 Sublicensing. GSK shall have the right to grant sublicenses to (a) Affiliates and/or (b) Third Parties who
receive a license to the Licensed Indications, to the license rights granted to GSK in Section 2.1 above, subject to the following terms and conditions: 
 (a) GSK may grant sublicenses to Affiliates and/or Third Parties: 
 (i) for Exclusive Vaccines [**] provided that the Sublicensee will practice the Licensed Patent Rights and Licensed Technology only to the
extent granted to GSK under this Agreement and GSK and the Sublicensee will comply with the remaining provisions of this Section 2.2. 
 (ii) for Co- exclusive and Non- exclusive Vaccines [**] provided that the Sublicensee will practice the Licensed Patent Rights and Licensed Technology only in the applicable country and only to the extent granted to
GSK under this Agreement; and that GSK and the Sublicensee will comply with the remaining provisions of this Section 2.2. 
 (b) GSK and (i) each Affiliate Sublicensee will sign a side letter under which the Affiliate Sublicensee will agree to be bound by the terms of this Agreement; and (ii) each Third Party Sublicensee shall enter into a written
agreement subject to, consistent with, and not to extend beyond the scope of GSK’s rights and obligations under, and the terms and conditions of, this Agreement, which written sublicense agreement shall require the Third Party Sublicensee to
agree to be bound by and comply with provisions that are consistent with the provisions of this Agreement. In addition, each such side letter or sublicense agreement shall require the Affiliate and/or Third Party Sublicensee, at the election of
Antigenics MA (to be made by Antigenics MA upon notice from GSK at the time the side letter or sublicense agreement is entered into) to either (i) [**] to [**] by the [**] and [**] of, and the [**] of [**] under, the [**] or (ii) [**] a
[**] within a [**] after the [**] of the [**], pursuant to which the 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 8 

 Confidential 
  

 
[**] shall be [**] to [**] from [**], or a [**] of [**] (either [**] or [**] as may be [**] by [**]) all of its [**] of [**] and [**] or its [**] will [**]
to [**] such [**] (up to [**]), provided that after the [**] (as defined in the [**]), any such [**] shall have the right to [**] (if [**] a [**] to [**] in accordance with the [**]) or [**] its [**] from [**]. In addition and notwithstanding the
foregoing, GSK may grant sublicenses to Affiliate subsidiaries controlled by GSK without entering into a written side letter or sublicense agreement with such subsidiaries, provided that GSK shall and hereby guarantees and remains primarily
responsible for the performance of such subsidiaries in accordance with this Agreement and the Supply Agreement.
 (c) GSK
shall remain responsible for compliance by any Sublicensee receiving a sublicense hereunder with all terms and conditions of this Agreement relevant to such Sublicensee. GSK shall promptly provide Antigenics MA with a copy of the relevant provisions
of such agreement entered into with any Sublicensee, which are reasonably necessary for Antigenics MA to verify consistency with the terms of this Agreement and/or Antigenics MA’s rights hereunder. 
 (d) Should this Agreement terminate for any reason, at GSK’s request and provided that GSK’s Third Party Sublicensee continues
to comply with the provisions of the written agreement to be entered into pursuant to Section 2.2 (c) above, the sublicense shall survive provided that Antigenics MA shall be substituted for GSK and become the direct licensor of GSK’s
Third Party Sublicensee, provided that Antigenics MA has approved or has not reasonably objected to such written agreement. In no event shall Antigenics MA have greater obligations under any such written agreement than Antigenics MA has under this
Agreement. 
 In addition, and for the avoidance of doubt notwithstanding the foregoing provisions, GSK, its Affiliates and Sublicensees shall have the right
to collaborate with Third Parties for the development of Licensed Vaccines and/or to engage with a Third Party to carry out clinical trials in the ordinary course of business to develop Licensed Vaccines and to engage Third Party distributors in the
ordinary course of business to sell Licensed Vaccines in accordance with this Agreement without Antigenics MA’s further consent and without a formal sublicense agreement, provided that such arrangements do not otherwise compromise Antigenics
MA’s (or its Affiliates) rights under this Agreement or the Supply Agreement. 
 2.3 Non-Assertion. GSK covenants and agrees not
to assert against Antigenics MA, its Affiliates or licensees or sublicensees any claim for [**] with [**] to [**] falling within the GSK Patent Rights. To the extent that GSK grants any sublicenses for the performance of GSK’s rights
or obligations hereunder, GSK shall obtain the same non-assertion covenant and agreement for Antigenic MA, its Affiliates or licenseese or sublicensees from its Sublicensees, whether Affiliates or Third Party Sublicensees (in the
side letter or sublicense agreement, as applicable), and Antigenics MA and its Affiliates and licensees and sublicensees shall be expressly acknowledged as third party beneficiaries under such non-assertion provisions.
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 9 

 Confidential 
  

 2.4 No Other Rights. Except for the express licenses granted pursuant to this Article 2, no
license, express or implied, is granted by either Party to the other Party under any intellectual property rights owned or controlled by such Party. 
 2.5 Conversion. GSK shall have the right to convert the license to Exclusive Vaccines into a non-exclusive or co-exclusive license and to convert the license to Co-Exclusive Vaccines into a non-exclusive
license upon notification to Antigenics MA [**] from the [**] as described in Section [**] or [**] as appropriate. 
 3. Consideration to Antigenics
MA. 
 3.1 Milestone Payments. As partial consideration for the license rights granted to GSK pursuant to this Agreement, GSK
shall make one-time, non-refundable, non-creditable development milestone payments to Antigenics MA within [**] after achievement of each of the [**] milestones by GSK or its Sublicensees set forth below as follows: 
  

			
	 Milestone
	  	 [**] Licensed
Vaccine [**]

	 [**] of [**] in any country of the Territory
	  	US [**]
	 [**] of [**] in any country of the Territory
	  	US [**]

 GSK shall notify Antigenics MA within [**] of the achievement of any of the above [**] milestones and Antigenics
MA shall send the corresponding invoices to GSK to the address specified in Section 12.12 or to such other address as may be later specified by GSK below to the attention of GSK’s Licensing Manager. 
 3.2 Royalties. As further consideration for the license rights granted to GSK hereunder, commencing with the First Commercial Sale of Licensed
Vaccines by GSK or its Sublicensees, for each Licensed Vaccine whose manufacture, use, sale, offer for sale, or importation would, absent the license rights granted to GSK hereunder, infringe one or more Valid Claims of the Licensed Patent Rights,
the following royalties shall apply and be payable on Net Sales in countries where such Licensed Vaccine is covered by a Valid Claim of the Licensed Patent Rights in the country of sale: 
 (a) [**] for (i) Exclusive Vaccines, or (ii) any other Licensed Vaccines for use in the Licensed Indication of cancer covered by
a Valid Claim of a [**] Patent, provided however that in the event that a [**] has a [**] (as defined below) in a [**], then the royalty rate on Licensed Vaccines covered by a Valid Claim of a [**] Patents would be [**] in [**], and provided further
that in the event that [**] has a [**] in a [**] 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 10 

 Confidential 
  

 
[**], then the royalty rate on Licensed Vaccines covered by a Valid Claim of a [**] Patents would be [**] in [**]; 
 (b) [**] for Co-exclusive Vaccines; and 
 (c) [**] for Non-exclusive Vaccines. 
 As used herein, [**] means a Vaccine product for use in the [**] covered by the [**]
Patent for use in the [**] covered by the [**] Patent. For the avoidance of doubt, Antigenics MA shall not be authorized to grant to any Third Party, as of the Effective Date, any further license under [**] Patent for use in [**] and [**].

 Except as specifically provided herein, the foregoing royalties shall not be subject to any reductions, including without limitation, for Third Party
patent rights, Third Party competing products, or the like. In addition, in the event that any Licensed Vaccine (including any Combination Vaccine) contains antigens in Licensed Indications identified in more than one of Exhibits B, C and D
then [**]. 
 3.3 Sublicense Revenue. In addition to the royalties payable under Section 3.2 above, GSK shall pay to Antigenics
MA [**] of any Sublicense Revenue received by GSK. These Sublicense Revenue payments shall be nonrefundable and payable [**] after GSK receives the relevant payment. 
 4. Payments, Reports and Records. 
 4.1 First Commercial Sale. GSK shall notify Antigenics MA
of the occurrence of the First Commercial Sale of each therapeutic Licensed Vaccine and each prophylactic Licensed Vaccine in the first country of the Territory within [**] of its occurrence. 
 4.2 Payments. Commencing with the First Commercial Sale of the first Licensed Vaccine in any country, GSK shall furnish to Antigenics MA a written
report within [**] showing, on a country-by-country basis: (i) Gross Sales by GSK and its Affiliates and Third Party Sublicensees during the reporting period listed by country; (ii) the Net Sales of all such Licensed Vaccines sold, and
qualifying deductions as described in Section 1.22, listed by category of deductions; (iii) the royalties payable in United States dollars which shall have accrued hereunder in respect of such sales; (iv) withholding taxes, if any,
required by law to be deducted in respect of such sales, as applicable; (v) the exchange rates used in determining the amount of United States dollars as provided in Section 4.4 below; and (vi) the Sublicense Revenue payments paid or
payable for such period. All royalty payments shown to have accrued to Antigenics MA by each report provided for under this Section shall be due and payable on the date such report is due. If no payments are due for any reporting period hereunder,
GSK shall so report. All payments to Antigenics MA under this Agreement shall be made in United States dollars by check payable to “Antigenics, Inc.” or, if requested by Antigenics MA, by wire transfer to an account designated by
Antigenics MA. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 11 

 Confidential 
  

 4.3 Withholding Taxes. All royalty payments are exclusive of all federal, state, local and
foreign taxes, levies, and assessments, duties, customs and similar charges. GSK shall be responsible for any and all such applicable charges incident to the payments to Antigenics MA under this Agreement, other than taxes on Antigenics MA’s
income. When Antigenics MA has the legal obligation to collect such taxes, the appropriate amount shall be paid by GSK (by adding such amount to the payment to Antigenics MA under Section 4.2), unless GSK provides Antigenics MA with a valid tax
exemption certificate authorized by the appropriate taxing authority. In the event that GSK is required by applicable law to make deductions or withholdings from payments to Antigenics MA hereunder, then GSK shall pay such additional amounts to
Antigenics MA as may be necessary to assure that the actual amount received by Antigenics MA after deduction or withholding shall equal the amount that would have been received if such deduction or withholding were not required. 
 4.4 Exchange Rates. If GSK (or its Affiliates or Third Party Sublicensees ) receives revenues from the sale of Licensed Vaccines in currency other
than United States dollars, revenues shall be converted to United States dollars at the conversion rate for foreign currency as published in the The Wall Street Journal, published on the last Business Day of the applicable calendar quarter.

 4.5 GSK’s Recordkeeping and Inspection. After the date of First Commercial Sale of the first Licensed Vaccine, GSK shall keep,
and shall cause its Affiliates and Third Party Sublicensees to keep, for at least [**] records of all sales of Licensed Vaccines in sufficient detail to permit Antigenics MA to confirm the accuracy of GSK’s royalty and Sublicense Revenue
payment calculations. At the request of Antigenics MA, upon at least [**] prior written notice to GSK or its Affiliate or Third Party Sublicensee and at the expense of Antigenics MA (except as otherwise provided below), GSK or its Affiliate or Third
Party Sublicensee shall permit an experienced, independent certified public accountant selected by Antigenics MA and reasonably acceptable to GSK or its Affiliate or Third Party Sublicensee to inspect, during regular business hours, any such records
of GSK or its Affiliate or Third Party Sublicensee for the then-preceding [**] solely to the extent necessary to verify such calculations provided that such inspection shall not take place more often than once a year, and shall not cover such
records for more than the preceding [**] and shall not cover the same records more than once unless this is reasonably necessary for confirming the accuracy of existing records. Results of any such inspection shall be made available to both Parties.
If such inspection reveals a deficiency in the calculation of royalties and/or Sublicense Revenue payments resulting in an underpayment to Antigenics MA by [**], GSK shall pay all costs and expenses of such inspection if such inspection reveals an
overpayment of royalties and/or Sublicense Revenue payments to the benefit of Antigenics MA of [**], Antigenics MA shall refund to GSK any overpaid amounts within [**] after results of such inspection become available. Any deficiencies found shall
be payable by GSK within [**] of receipt of invoice from Antigenics MA. 
 4.6 Interest on Late Payments. Any payment not timely made
shall bear interest at a rate equal to [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 12 

 Confidential 
  

 5. Annual Update, Diligence and Related Responsibilities. 
 5.1 Annual Update. GSK agrees to use its Commercially Reasonable Efforts to conduct its development activities substantially in accordance with
the Annual Update prepared by GSK consistent with this Agreement. A copy of the Annual Update will be provided to Antigenics MA each year, with a copy to the Steering Committee for their annual review and discussion. The initial Annual Update is
attached hereto as Exhibit A. GSK will use, and will ensure that its Sublicensees use, Commercially Reasonable Efforts to execute and to perform, or cause to be performed, the development activities set forth in the Annual Update, in each
case in good scientific manner and in compliance with applicable laws, rules, regulations, and guidelines. In addition, by or promptly after execution of this Agreement, GSK will provide Antigenics MA with a summary of results achieved as part of
its development programs with respect to [**]. In addition, GSK shall provide Antigenics MA with a detailed status update and development plan for its QS-21 activities in the Licensed Indications of [**] within [**] of the [**] of the
Effective Date. Information provided hereunder shall be treated as Confidential Information in accordance with this Agreement. 
 5.2
Diligence. GSK shall use Commercially Reasonable Efforts to develop and commercialize the Licensed Vaccines in the Territory. In addition to such development and commercialization efforts, GSK will use Commercially Reasonable Efforts to
provide appropriate medical affairs personnel to support the Licensed Vaccines in the Territory during the Term. GSK’s development and commercialization activities will be consistent with the Annual Update. For sake of clarity, it is hereby
understood that nothing contained in this Agreement require GSK to pursue the development or commercialization of all Licensed Vaccines at the same time. 
 5.3 Diligence Inquiry. If Antigenics MA believes that GSK has failed to apply Commercially Reasonable Efforts to commercialize the Licensed Vaccines as provided in Section 5.2 above, it will notify GSK in
writing, and within thirty (30) days of receipt of such notice, GSK will submit a report to Antigenics MA containing sufficient detail to allow Antigenics MA to verify GSK’s compliance. If, after receiving the report, Antigenics MA is not
satisfied that GSK has complied with its diligence requirements as described above, Antigenics MA may convene a Special Meeting of the Steering Committee, attended by appropriate representatives from each Party’s business, research and
development, commercial and/or legal departments, as provided in Section 5.4 below to address the matter. 
 5.4 Special Meeting of
Steering Committee. If Antigenics MA believes that GSK has failed to comply with its diligence obligations under this Article 5, then Antigenics MA may, by written notice to GSK, convene a special meeting of the Steering Committee to discuss the
matter (a “Special Meeting”). Such notice may include a general statement of the areas of concern to Antigenics MA. The Parties will convene the Special Meeting no later than [**] after such notice is given. At the Special Meeting,
the Steering Committee will discuss the areas of concern to Antigenics MA and the additional actions (if any) GSK could 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 13 

 Confidential 
  

 
take to address such concerns. If, after a Special Meeting, the Parties still disagree on whether GSK has complied with its diligence requirement under the
Annual Update, then [**]. If GSK agrees that additional actions need to be taken, GSK will provide Antigenics MA with a proposal within [**] describing the actions that GSK proposes to take to meet such obligation. If Antigenics MA then notifies GSK
in writing that Antigenics MA agrees that such proposal describes actions sufficient to meet such obligation, then GSK will carry out the actions described in such proposal. If Antigenics MA disagrees with GSK as to the sufficiency of the actions
described in such proposal to meet such obligation, and the Parties are unable to resolve such disagreement within [**]. Any agreed proposal will be deemed to constitute an amendment to the relevant Annual Update. 
 5.5 Cessation of Activities. Without in any way limiting the foregoing, if GSK elects to stop the development or commercialization of Licensed
Vaccines in all countries, GSK shall promptly [**], and thereafter, [**]. 
 5.6 Compliance. GSK shall comply, and shall cause
its Sublicensees to comply, with all applicable federal and state laws, rules, regulations and guidelines and the provisions of Section 2.3 of the Supply Agreement in connection with its performance under this Agreement and the development and
commercialization of Licensed Vaccines. 
 5.7 Cooperation of Antigenics MA. Antigenics MA shall cooperate with and assist GSK in the
preparation and filing of information with respect to QS-21 for use in any regulatory filings throughout the Territory with respect to any Licensed Vaccine as provided for under the Supply Agreement. 
 5.8 Exchange of Safety Information. 
 (a) During the Term of this Agreement, each Party shall use customary pharmacovigilance processes relevant to manufacture or use of a pharmaceutical grade bulk drug substance to monitor and promptly disclose to the
other Party information of which it becomes aware regarding any actual or potential significant safety issue relating to QS-21. For these purposes, the term “significant safety issue” includes, without limitation, the following events (or
events likely to result in the following): 
 (i) The suspension or termination of a clinical trial or clinical trial program
for QS-21 due to an actual or potential safety issue relating to administration or utilization of QS-21 either alone or as a component of a Licensed Vaccine or other product; 
 (ii) the suspension, revocation or variation of a Marketing Approval or a regulatory authorization (such as a clinical trial
authorization) for QS-21 due to an actual or potential safety issue relating to administration or utilization of QS-21 either alone or as a component of a Licensed Vaccine or other product; 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 14 

 Confidential 
  

 (iii) the voluntary withdrawal of QS-21 or a Licensed Vaccine or other product from
the market due to an actual or potential safety issue relating to QS-21; 
 (iv) a change to the protocol of a clinical trial
in which the QS-21 is being used due to an actual or potential safety issue relating to the utilization or administration of QS-21 either alone or as a component of a Licensed Vaccine or other product; 
 (v) a change to the Marketing Approval by way of a restriction of the indications, in the indicated patient population, in the
circumstances of use or administration, or a change to the contraindications, precautions and/or warnings of a Licensed Vaccine or other product, provided, however, such change is prompted by an actual or potential safety issue relating to
administration or utilization of QS-21 either alone or as a component of a Licensed Vaccine or other product; 
 (vi) an
indication of lack of efficacy of QS-21 where this could lead to a significant health hazard to the exposed patient population; 
 (vii) issuance of a Dear Doctor or Dear Healthcare Provider letter (or equivalent communication) relating to a safety issue associated with the administration or utilization of QS-21 either alone or as a component of a Licensed Vaccine or
other product; 
 (viii) an adverse effect upon the overall balance of benefits and risks afforded by QS-21 such that it could
lead to a significant change in the evaluation of that balance. 
 Such information shall be communicated no later than three
(3) business days following the occurrence of such an event. 
 (b) Each Party shall promptly notify the other Party of
the receipt of an enquiry from a regulatory authority regarding an actual or potential significant safety issue associated with QS-21 when administered either alone or as a component of a Licensed Vaccine or other product. For these purposes, the
term “significant safety issue” includes, without limitation, the events listed in Sections 5.8 (a)(i)-(viii). Such notification shall be provided within five (5) business days of receiving the enquiry. 
 (c) The Party receiving the query shall submit the response it considers appropriate and shall simultaneously provide a copy thereof to
the other Party. For avoidance of doubt, GSK shall have the right to provide such response and related safety information for such purposes to its Sublicenses, and Antigenics MA shall have the right to provide such response and related safety
information for such purposes to its Affiliates and QS-21 licensees and QS-21 customers. 
  

 15 

 Confidential 
  

 6. Supply Agreement. 
 The Parties acknowledge and agree that, pursuant to a separate Manufacturing Technology Transfer and Supply Agreement to be executed by the Parties contemporaneously with this Agreement (the “Supply
Agreement”), Antigenics MA shall transfer certain QS-21 manufacturing rights to GSK on commercially reasonable terms and conditions in line with the Supply Agreement. Under the Supply Agreement, GSK shall have the right to manufacture its
own supply of QS-21, subject to Antigenics MA’s retained rights. GSK shall not manufacture or have any Third Party or Affiliate manufacture QS-21 except in accordance with this Agreement and the Supply Agreement. 
 7. Representations and Warranties; Disclaimer. 
 7.1 Representations and Warranties of GSK. GSK represents, warrants and covenants to Antigenics MA as follows: 
 (a) GSK is a corporation duly organized, validly existing and in good standing under the laws of Belgium. GSK has all requisite corporate power to own and operate its properties and assets and to carry on its business
as presently being conducted and as proposed to be conducted. GSK has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement, and to carry out and perform its obligations under the terms
of this Agreement; and 
 (b) the execution and delivery of this Agreement and the performance of the transactions
contemplated hereby have been duly authorized by all appropriate GSK corporate action. The performance by GSK of any of the terms and conditions of this Agreement on its part to be performed does not and will not constitute a breach or violation of
any other agreement or understanding, written or oral, to which it is a party. 
 (c) In addition, without admitting any
fault, GSK represents, warrants and covenants that is has abandoned or will timely abandon and not pursue in the future any of the patents or patent applications listed on Exhibit E attached hereto and incorporated herein. 
 7.2 Representations and Warranties of Antigenics MA. Antigenics MA represents, warrants and covenants to GSK as follows: 
 (a) Antigenics MA is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of
Massachusetts. Antigenics MA has all requisite corporate power to own and operate its properties and assets and to carry on its business as presently being conducted and as proposed to be conducted. Antigenics MA has, and will have on all relevant
dates, all requisite legal and corporate power to execute and deliver this Agreement and to carry out and perform its obligations under this Agreement. 
 (b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate Antigenics MA corporate action. The performance by Antigenics
MA of any of the terms and conditions of this Agreement on its part to be performed does not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party, and that Antigenics 

  

 16 

 Confidential 
  

 
MA has not entered and will not enter into any agreement with a Third Party which would conflict with or be in breach of the rights granted to GSK hereunder.
Antigenics MA has the full right and legal capacity to provide in the Territory all rights to the Licensed Technology and Licensed Patent Rights in the Licensed Indications granted to GSK hereunder. 
 (c) to its knowledge as of the Effective Date, all relevant intellectual property rights of Antigenics MA or its Affiliates [**] for [**]
to [**] and [**] in accordance with this Agreement are [**] either in [**] or in [**]. 
 (d) to its knowledge as of the
Effective Date, Antigenics MA owns the right, title and interest in the Licensed Patent Rights set forth in Exhibit I, or otherwise has the right to grant the licenses hereunder to such Licensed Patent Rights, and in the Licensed Know-how
provided to GSK and that it otherwise has the right to enter into this Agreement. [**]. 
 (e) Nothing in this Agreement shall
be construed as a warranty that Licensed Patent Rights are valid or enforceable. Antigenics MA hereby represents that it has no present actual knowledge from which it can be inferred that Licensed Patent Rights are invalid. 
 (f) Antigenics MA warrants and represents that it has no present actual knowledge of the existence of any pre-clinical or clinical data or
information concerning QS21 which suggests that there may exist quality, toxicity, safety and/or efficacy concerns which may materially impair the utility and/or safety of QS21. 
 7.3 Disclaimer of Warranty. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT, ANTIGENICS MA MAKES NO REPRESENTATIONS AND EXTENDS NO
WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS INCLUDING WITHOUT LIMITATION WARRANTIES OF THE VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENT RIGHTS, MERCHANTABILITY, FITNESS FOR
A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF ANY THIRD PARTY PATENTS OR PROPRIETARY RIGHTS. ALL UNIFORM COMMERCIAL CODE WARRANTIES AND UNITED NATIONS CONVENTION ON THE INTERNATIONAL SALE OF GOODS WARRANTIES ARE EXPRESSLY DISCLAIMED BY ANTIGENICS MA.

 8. Liability. 
 8.1 Indemnification
by GSK. GSK shall indemnify, defend and hold harmless Antigenics MA and its Affiliates and its and their respective directors, officers, employees and agents, and its and their respective successors and/or heirs (current and former) and assigns
(the “Antigenics MA Indemnitees”) against any liability, damage, loss, cost or expense (including reasonable legal fees and expenses of litigation) (collectively, “Liabilities”) suffered, incurred by or imposed upon
any such Antigenics MA Indemnitees resulting from any Third Party claim, 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 17 

 Confidential 
  

 
demand, suit, action or judgment (hereinafter collectively referred to as “Claims”) (including without limitation, arising from any theory of
product liability (including without limitation actions in the form of tort, warranty or strict liability)) to the extent arising out of or resulting from the development, manufacture, use, sale, offer for sale, importation or exportation of any
Licensed Vaccine, or otherwise resulting from activities undertaken by or on behalf of GSK hereunder or under the Prior Agreement including resulting from Third Party allegation that a Combination Vaccine breached or infringed the Third Party’s
rights granted by Antigenics MA to that Third Party, except to the extent (if any) that such Liability is attributable to (a) the negligence or intentional misconduct of any Antigenics MA Indemnitee, or (b) the failure of QS-21 delivered
by or on behalf of Antigenics MA to meet the specifications set forth in the Supply Agreement at the time of shipment thereunder. 
 8.2
Indemnification by Antigenics MA. Antigenics MA agrees to indemnify, defend and hold harmless GSK, its Affiliates and its and their respective directors, officers, employees and agents, and its and their respective successors and/or heirs
(current and former) and assigns (the “GSK Indemnitees”) against any and all Liabilities suffered, incurred by or imposed upon any such GSK Indemnitees in connection with any Third Party Claim (including without limitation, arising
from any theory of product liability (including without limitation actions in the form of tort, warranty or strict liability)) to the extent arising from or resulting out of Antigenics MA’s negligence or intentional misconduct, except to the
extent (if any) that such Liability is attributable to the negligence or intentional misconduct of any GSK Indemnitee. 
 8.3 Notice and
Cooperation. Any Antigenics MA Indemnitee or GSK Indemnitee (each an “Indemnitee”) intending to claim indemnification under this Article 7 shall promptly notify the other Party (the “Indemnifying Party”) of any Claim
after the Indemnitee is aware thereof, setting forth the nature of the Claim and the basis for indemnification hereunder, and the Indemnifying Party shall assume, at its sole cost and expense, the defense of the Claim with counsel mutually
satisfactory to the Parties; provided, however, that any Indemnitee shall have the right to retain its own counsel reasonably acceptable to the Indemnifying Party, at the expense of the Indemnifying Party, if representation of such Indemnitee
by the counsel retained by the Indemnifying Party would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other Party represented by such counsel. The Indemnitee shall cooperate fully with the
Indemnifying Party in such defense and will permit the Indemnifying Party to conduct and control such defense and disposition of such Claim including all decisions relative to litigation, appeal and settlement provided that (i) the Indemnifying
Party agrees to keep the Indemnitee informed of the progress in the defense and disposition of such Claim and to consult with the Indemnitee with regard to any proposed settlement; and (ii) the Indemnifying Party agrees not to enter into any
settlement which would have a material adverse effect on the other Party without prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. This indemnity agreement shall not apply to amounts paid in
settlement of any Liability if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnifying Party promptly after the Indemnitee
receives notice of or otherwise becomes aware of any such Claim, if prejudicial to its ability to defend such Claim, shall relieve the Indemnifying Party of any liability to the Indemnitee under this indemnity agreement. 
  

 18 

 Confidential 
  

 8.4 LIMITATION OF LIABILITY. EXCEPT A) WITH RESPECT TO LIABILITY RELATING TO THIRD PARTY
CLAIMS UNDER SECTIONS 8.1 OR 8.2, B) LIABILITY FOR BREACH OF ARTICLE 9, AND C) CLAIMS FOR MISUSE, MISAPPROPRIATION OR INFRINGEMENT OF INTELLECTUAL PROPERTY, IT IS AGREED BY THE PARTIES THAT NEITHER PARTY NOR ITS AFFILIATES SHALL BE LIABLE TO THE
OTHER PARTY OR ITS AFFILIATES FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES (OTHER THAN REVENUES COMPRISING ROYALTIES OR OTHER PAYMENTS TO BE EARNED AND PAID TO A PARTY BY THE OTHER
PARTY UNDER THIS AGREEMENT) OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS
ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 
 8.5 Insurance. During the Term and for a period of [**] after the [**] of
Licensed Vaccine by GSK, its Affiliates, Third Party Sublicensees or distributors, GSK shall either self-insure through a GlaxoSmithKline plc program, or obtain and carry, and shall cause its Sublicensees to obtain and carry, in full force and
effect product liability insurance in amounts which are reasonable and customary in the pharmaceutical industry for similar products. Upon request by Antigenics MA, GSK shall provide, and shall cause its Sublicensees to provide, Antigenics MA with
appropriate certificates of insurance unless GSK is self-insured. 
 9. Confidentiality. 
 9.1 “Confidential Information” shall mean any technical, scientific or business information furnished by or on behalf of one Party or
its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”) in connection with this Agreement, the Supply Agreement or the Prior Agreement, or the activities contemplated
hereunder and thereunder, regardless of whether such information is specifically designated as confidential and regardless of whether such information is in oral, written, electronic or other form. The terms of this Agreement shall be considered
Confidential Information of both Parties, subject to the provisions of this Article 9 and Section 12.6. Confidential Information shall not include information that: 
 (a) is generally available in the public domain or thereafter becomes available to the public through no act of the Receiving Party; or

 (b) was independently known to the Receiving Party prior to receipt thereof or was discovered independently by an employee
of the Receiving Party who had no access to the information supplied by or on behalf of the Disclosing Party; or 
 (c) was
made available to the Receiving Party as a matter of lawful right by a Third Party who had no obligations of confidentiality to the Disclosing Party. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 19 

 Confidential 
  

 9.2 Obligations. The Receiving Party agrees that it shall not, without the prior written
consent of the Disclosing Party, directly or indirectly: 
 (a) make any use, of any portion of the Confidential Information
of the Disclosing Party for purposes other than those set forth in this Agreement; 
 (b) disclose or transfer any portion of
the Confidential Information to any person, except that the Receiving Party may disclose or permit the disclosure of Confidential Information to its Affiliates and sublicensees and subcontractors and partners and its and their respective directors,
officers, employees, consultants, and advisors, and investors and potential investors in connection with a general financing transaction, who have an ethical or fiduciary duty to the Receiving Party or are otherwise obligated to maintain the
confidential nature of such Confidential Information and who need to know such Confidential Information for the purposes set forth in this Agreement or for other legitimate business purposes; 
 Notwithstanding the above, the Receiving Party may disclose Confidential Information of the Disclosing Party when required by applicable laws or
government rules or regulations (including without limitation, applicable securities regulations), provided that to the extent reasonably possible, the Receiving Party provides reasonable prior written notice of such disclosure to the Disclosing
Party and takes reasonable efforts to avoid and/or minimize the extent of disclosure. 
 9.3 Upon expiration or termination of this Agreement
and upon request of the Disclosing Party, all copies of any Disclosing Party’s Confidential Information shall be returned to the Disclosing Party, except that each Receiving Party may retain one (1) copy of the Confidential Information
received hereunder in the possession of its legal counsel, solely for monitoring its obligations under this Agreement. 
 9.4 No option,
license, or conveyance of such rights, express or implied, is granted to the Receiving Party in connection with any Confidential Information disclosed by the Disclosing Party, except for the express licenses granted in Article 2. If any such rights
are to be granted to the Receiving Party, such grant shall be expressly set forth in a separate written instrument. 
 10. Term and Termination.

 10.1 Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated as provided in this Article 10,
shall expire upon the later of (i) the expiration of the last to expire of Valid Claims of the Licensed Patent Rights or (ii) the date royalties and other payments are no longer payable by GSK to Antigenics MA under Article 3 hereof (the
“Term”). 
 10.2 Material Breach. Failure by either Party to comply with any of the material obligations or
representations or warranties contained in this Agreement shall entitle the other Party to give to the Party in default written notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within
thirty (30) days for payments or sixty (60) days for other material breaches after the receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement 

  

 20 

 Confidential 
  

 
and in addition to any other remedies available to it by law or in equity, to terminate this Agreement effective upon written notice to the other Party. The
right of a Party to terminate this Agreement, as hereinabove provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous default. For the purposes of this Section, a material breach of the Supply
Agreement by one Party shall be deemed a material breach and default of this Agreement by such Party, and shall entitle the other Party to give notice of default under this Section. In addition, Antigenics MA shall have the right to terminate this
Agreement and/or the Supply Agreement immediately upon written notice to GSK in the event that GSK or its Affiliates challenge, or direct or assist a Third Party to challenge, the validity, patentability or enforceability of, or otherwise oppose
any, Licensed Patent Rights. 
 10.3 Termination by GSK. GSK may terminate this Agreement, in whole or in part on a Licensed Vaccine
by Licensed Vaccine basis, or on Licensed Patent Right by Licensed Patent Right basis, or on a country-by-country basis or for the whole Territory without cause, by giving [**] prior written notice to Antigenics MA. 
 10.4 Termination or Continuation for Bankruptcy of Antigenics MA. 
 (a) GSK may terminate this Agreement if, at any time, Antigenics MA shall file in any court or agency pursuant to any statute or
regulation of (the United States or of) any (individual) state or (foreign) country, a petition in bankruptcy or insolvency or for reorganisation or for an arrangement or for the appointment of a receiver or trustee of the party or of its assets, or
if Antigenics MA proposes a written agreement of composition or extension of its debts, or if Antigenics MA shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed [**]
after the filing thereof, or if Antigenics MA shall propose or be a party to any dissolution or liquidation, or if Antigenics MA shall make an assignment for the benefit of creditors. 
 (b) In the alternative, notwithstanding the bankruptcy of Antigenics MA or the impairment of performance by Antigenics MA of its
obligations under this Agreement as a result of bankruptcy or insolvency of Antigenics MA, GSK shall be entitled to retain the licenses granted herein in lieu of termination of this Agreement. For the purposes of this Agreement all rights and
licenses granted under or pursuant to any Section of this Agreement are rights to “intellectual property” (as defined in Section 101(35A) of Bankruptcy Code). Antigenics MA hereby acknowledges that (i) Licensed Patent Rights and
Licensed Know-How, (ii) the Manufacturing Technology (as defined in the Supply Agreement), and (iii) the Manufacturing Technology Package (as defined in the Supply Agreement), in each case, that relate to such intellectual property,
constitute “embodiments” of such intellectual property pursuant to Section 365(n) of the Bankruptcy Code. Antigenics MA agrees not to interfere with GSK’s exercise, pursuant to Section 365(n) of the Bankruptcy Code, of
rights to intellectual property granted hereunder and embodiments thereof and agrees to use reasonable efforts to assist GSK to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably
necessary for GSK to exercise such rights pursuant to Section 365(n) of the Bankruptcy Code. 
 (c) Effect of
Termination. Any expiration or termination of this Agreement shall not relieve either Party from any obligation which accrued prior to such expiration or 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 21 

 Confidential 
  

 
termination. The provisions of Articles 6, 7, 8, and 9, and Sections 2.3, 3.1, 4.2, 4.3, 4.4, 4.5, 4.6, 5.1 (for the term of the Supply Agreement), 5.8 (for
the term of the Supply Agreement), 11.1, 11.2(a) (first sentence only), 11.2(b), 12.1, 12.5, 12.6, 12.8, 12.11, and 12.12 and this Section 10.4 (c) shall survive expiration or termination of this Agreement for any reason. In addition,
unless this Agreement is sooner terminated as provided in this Article 10, upon expiration of the Term of this Agreement pursuant to Section 10.1 above, the license rights granted to GSK under Section 2.1 (and the sublicense rights granted
under Section 2.2) shall be deemed royalty-free, non-exclusive and perpetual. Any sublicense agreement reviewed and approved or not reasonably objected by Antigenics MA between GSK and a Third Party Sublicensee shall survive termination of this
Agreement in accordance with Section 2.2 (d) provided and for so long as the Sublicensee continues to meet its contractual obligations. In that case the Third Party Sublicensee shall become a direct licensee of Antigenics MA. In addition,
in the event that GSK terminates this Agreement in its entirety in accordance with Section 10.3 hereof (other than for a “significant safety issue” (as defined in Section 5.8) relating to QS-21, as reasonably demonstrated by
GSK), and the aggregate effect of such termination(s) is such as to reduce GSK’s projected supply requirements for QS-21 under the Supply Agreement by more than [**], and if at the time of such termination(s) Antigenics MA shall have made
irrevocable commitments for the establishment of capacity to supply GSK’s requirements, GSK shall pay Antigenics MA a [**] to [**] for such excess capacity. Such payment shall be [**] and paid by GSK within [**] of [**]. 
 11. Patent Rights. 
 11.1 Inventions. Title to
any inventions will follow inventorship, as determined in accordance with United States laws of inventorship and written evidence of the Parties. Designation of inventors on any patent application is a matter of law and will be solely within the
discretion of qualified patent counsel of Antigenics MA and GSK. Notwithstanding the foregoing, in the event that GSK breaches the representation, warranty and covenant contained in Section 7.1(c) of this Agreement, then in addition to any
right or remedy Antigenics MA may have available hereunder, or in law or equity, GSK shall assign and hereby does assign one half (1/2) undivided interest in and to any patent rights pursued in violation of Section 7.1(c) to Antigenics MA
or its designee. 
 11.2 Patent Prosecution. 
 (a) Licensed Patent Rights. Antigenics MA, by counsel it selects, shall have the sole right, but not the obligation, to prosecute
and maintain the Licensed Patent Rights in Antigenics MA’s name and in countries designated by Antigenics MA at the sole discretion of Antigenics MA. If Antigenics MA intends to abandon or otherwise cause or allow any of the Licensed Patents
Rights to be forfeited, it shall inform GSK reasonably in advance and GSK shall have the right but no obligation to assume responsibility for the prosecution and maintenance of any such Licensed Patent Right claiming [**] in Antigenics MA’s
name, subject to, and consistent with, Antigenics MA contractual obligations to Third Parties. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 22 

 Confidential 
  

 (b) GSK Inventions. GSK, by counsel it selects, shall have the sole right, but
not the obligation, to prepare, file, prosecute and maintain any GSK Patent Rights in GSK’s name and in countries designated by GSK at the sole discretion of GSK. 
 11.3 Third Party Infringement. Each Party shall promptly notify the other Party in writing of any alleged infringement of the Licensed Patent Rights and/or of any declaratory judgment actions brought against
the Licensed Patent Rights, and of any available evidence thereof. Antigenics MA shall have the sole right, but not the obligation, under its own control [**], to prosecute any Third Party infringement of the Licensed Patent Rights and/or to defend
the Licensed Patent Rights in any declaratory judgment action brought by a Third Party which alleges [**]. Antigenics MA may enter into any settlement, consent judgment or other voluntary final disposition of any infringement or declaratory judgment
action hereunder without the prior written consent of GSK provided that [**]. 
 11.4 Infringement Allegations. In the event that a
Third Party asserts or alleges that a Licensed Vaccine manufactured or sold by GSK infringes a patent or other proprietary right of such Third Party (other than actions relating solely to the Licensed Patent Rights, such as actions alleging that the
Licensed Patent Rights are dominated by Third Party patent rights or declaratory judgment actions brought against the Licensed Patent Rights), GSK shall have the right but not the obligation to assume the defense of such claim. Antigenics MA may
participate in the defense of such claim through counsel of its own choosing and at its sole expense if any such claim relates to or would in any way affect the Licensed Technology or Licensed Patent Rights. In the event that Antigenics MA receives
notice of such assertion or allegation, Antigenics MA shall notify GSK of such allegation or assertion. GSK may enter into any settlement, consent judgment, or other voluntary final disposition of any infringement action under this Section 11.4
that impacts or affects GSK’s ability to manufacture, use, sell, offer to sell, or import Licensed Vaccines pursuant to the license rights granted hereunder under the Licensed Patent Rights without the prior written consent of Antigenics MA,
except if any such settlement, consent judgment, or other voluntary final disposition will affect the Licensed Technology or Licensed Patent Rights in any manner (including without limitation, the validity, enforceability, or use of the Licensed
Technology or Licensed Patent Rights), in which case GSK shall obtain the prior written consent of Antigenics MA, which consent shall not be unreasonably withheld or delayed. 
 11.5 Antigenics MA and GSK shall recover their respective actual out-of-pocket expenses, or equitable proportions thereof, associated with any litigation
or settlement thereof from any recovery made by any Party. Any excess amount shall be shared between the Parties with GSK receiving [**] and Antigenics MA receiving [**] of such excess. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 23 

 Confidential 
  

 12. Miscellaneous. 
 12.1 Dispute Resolution. Except for the right of any Party to apply to a court of competent jurisdiction for a temporary restraining order, a
preliminary injunction or other equitable relief to preserve the status quo or prevent irreparable harm, any dispute, other than disputes regarding the construction, validity or enforcement of patents, arising between the Parties relating to,
arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be resolved as follows:

 (a) If the dispute cannot be resolved by the Parties through their duly authorized representatives within [**] (or the
Steering Committee, if applicable), the Chief Executive Officer of GSK (or his designee) and the Chief Executive Office of Antigenics, Inc., a Delaware corporation, the parent corporation of Antigenics MA (or his designee) shall meet in person at a
mutually acceptable time and location or by means of telephone or video conference within [**] of the matter being referred to them. 
 (b) If the Chief Executive Officer of GSK (or his designee) and the Chief Executive Officer of Antigenics, Inc. (or his designee) fail to first meet within [**] of the matter being referred to them, or if the dispute can not be resolved by
the Chief Executive Officer of GSK (or his designee) and the Chief Executive Officer of Antigenics, Inc. (or his designee) within [**] of the matter being referred to them, then either Party may bring such matter in a federal or state court in the
State of Delaware, to whose exclusive jurisdiction both Parties hereto consent. 
 12.2 No Partnership. Nothing in this Agreement is
intended or shall be deemed to constitute a partnership, distributorship, agency, employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at
all, specifically provided herein. 
 12.3 Assignments. This Agreement may not be assigned or otherwise transferred by either Party
without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that, GSK may, without such consent, assign this Agreement and any of its right or obligations hereunder to
its Affiliates or in connection with the transfer or sale of all or substantially all of the portion of its business to which this Agreement relates, or in the event of its merger or consolidation or reorganization or change in control; provided,
further, that the assigning Party shall deliver written notice of any such permitted assignment to the other Party. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties and the name
of a Party appearing herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any attempted assignment not in accordance with this Section
shall be void. 
 12.4 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all
such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 24 

 Confidential 
  

 12.5 No Name or Trademark Rights. Except as otherwise expressly provided herein, or expressly
set forth in the Supply Agreement, no right, express or implied, is granted by this Agreement to use in any manner the names “Antigenics, Inc.,” “GlaxoSmithkline plc.” or any contraction thereof or any other trade name or
trademark of Antigenics MA or GSK in connection with the performance of this Agreement. In addition, GSK agrees not use or apply for registration of any trademarks, tradedresses or tradenames pertaining to QS-21 (as opposed to trademarks pertaining
to Licensed Vaccines) in the Territory without Antigenics MA’s prior consent, which consent shall not be unreasonably withheld where the use of such trademarks, tradedresses or tradenames is required by applicable laws or regulations, provided
that such use by GSK is consistent with both Party’s internal trademark strategy. 
 12.6 Public Announcements. Upon the
execution of this Agreement, Antigenics MA (through its parent corporation, Antigenics, Inc.) shall be entitled to issue a press release regarding the subject matter of this Agreement and the Supply Agreement which [**] is attached hereto as
Exhibit G. After such initial press release, [**] issue a press release or public announcement relating to this Agreement or the Supply Agreement [**] Antigenics MA and its Affiliates shall have the right to disclose the information set forth
on Exhibit H without any further review and approval by GSK, provided that Exhibit H may be updated from time to time by mutual agreement of the Parties (including without limitation, [**] such [**] with [**]), or [**] where a [**] in
[**] would [**] any [**]. In the event that [**] or its [**] intends to [**] or [**] regarding the [**] and/or [**] of [**] (e.g., [**] of a [**] or [**] of a [**] (or similar [**] of a [**] and of a [**], or any [**] or [**] under [**] or the [**]
that would be [**] to be [**] to [**], each a “[**]”). [**] shall [**] to [**] to [**] a [**] pertaining to [**]. [**] shall be [**] a [**] of such [**] pertaining to [**] at least [**] the [**] to [**], and [**] shall [**] into [**],
including [**] to [**] if [**] or [**] any [**] with respect to [**]. In addition, in the event that [**] does not [**] any [**] or [**] as contemplated in the foregoing sentence, [**] shall [**] the [**] or [**] regarding (a) the [**] of any
[**], and/or (b) [**] under this Agreement or [**] and [**], provided that [**] pertaining to [**] at least [**] the [**] to [**] and [**], and [**] takes [**] into [**], including [**] to [**] with or otherwise [**] with respect to [**]. [**]
shall [**] within [**] of [**] of a [**] to [**] to [**] hereunder. In addition and 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 25 

 Confidential 
  

 
[**], and [**] and/or [**] shall have the right to make press releases or other public disclosures [**], to the extent a press release or other public
disclosure is required by applicable laws or regulations, including US securities laws, provided that, to the extent reasonably practical, [**] or [**] provides [**] of such release or disclosure. 
 12.7 Force Majeure. If any default or delay occurs which prevents or materially impairs a Party’s performance and is due to a cause beyond
the Party’s reasonable control, including but not limited to any act of god, flood, fire, explosion, earthquake, casualty, accident, war, revolution, terrorist acts, civil commotion, blockade or embargo, injunction, law, proclamation, order,
regulation or governmental demand, or acts, omissions or delays in acting by any Regulatory Authority, the affected Party promptly shall notify the other Party in writing of such cause and shall exercise diligent efforts to resume performance under
this Agreement as soon as possible. Neither Party shall be liable to the other Party for any loss or damage due to such cause. Neither Party may terminate this Agreement because of such default or delay, unless such event continues unabated for a
period of six (6) months, in which case the Party disadvantaged by such default or delay may, at its option, terminate this Agreement upon written notice to the other Party. 
 12.8 Entire Agreement of the Parties, Amendments. 
 (a) This Agreement, including the Exhibits attached hereto which are incorporated herein, and the Supply Agreement, constitute and contain the entire understanding and agreement of the Parties and cancels and
supersedes any and all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject matter hereof and thereof, including without limitation, the Prior Agreement. In addition
and for the avoidance of doubt, the Parties hereby agree that except for [**] described in subsection (b) of this Section 12.8, the Prior Agreement is terminated and fully superseded by this Agreement and the Supply Agreement as of the
Effective Date of this Agreement. Notwithstanding any provision to the contrary in the Prior Agreement, and except for [**] described in subsection (b) of this Section 12.8, no provision contained in that agreement shall survive
termination thereof. Notwithstanding the foregoing, each Party hereby agrees that, except for [**] described in subsection (b) of this Section 12.8, [**] which [**] the other [**] under the [**] of the [**], by [**] of any [**] of the [**]
out of any [**] or [**] prior to [**] of [**], is [**] or [**] hereby. No other waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each
of the Parties. 
 (b) The [**] as of [**] of [**], a [**] between the Parties [**] the [**] with respect to the [**] that
[**] including those [**] were or may be [**] in the future and/or [**] in [**] of the [**] of the [**], and that if such [**] are 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 26 

 Confidential 
  

 
[**] to be [**], that [**] would [**] have [**] in [**]. [**] such [**] and the [**] by [**]. The Parties have [**] this [**] and the [**] the [**] of the
[**], and shall be [**] to [**] pursuant to the [**] of the [**], modified as follows: 
 (i) The [**] of [**] hereunder [**]
on or before [**] following the [**]of [**] and any [**] is [**] to [**] for the [**] of such [**]. 
 (ii) The Parties agree
that the [**] or [**] to be [**] shall be [**] in the [**] of [**] and [**] to [**] the [**] and [**] of the [**]. The Parties further agree [**] in [**], should a [**], to [**] a [**] in lieu of a [**] of [**] to [**]; provided that if [**] cannot
[**] within [**] of [**] of the [**], the provisions for [**] a [**] under Section [**] of [**] shall apply. The Parties agree to [**] as a [**] for such [**]. 
 12.9 Severability. If any provision of this Agreement, or part thereof, is found by a proper authority to be unenforceable, that provision, or part thereof, shall be stricken and the remainder of this Agreement
will continue in full force and effect; provided, however, that the Parties shall renegotiate an acceptable replacement provision so as to accomplish, as nearly as possible, the original intent of the Parties. 
 12.10 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of
the provisions of this Agreement. 
 12.11 Applicable Law; Governing Language. This Agreement shall be governed and construed in
accordance with the laws of the State of Delaware, without regard to conflicts of laws principles. This Agreement has been prepared in the English language and the English language shall control its interpretation. All consents, notices, reports and
other written documents to be delivered or provided by a Party under this Agreement shall be in the English language, and in the event of any conflict between the provisions of any document and the English language translation thereof, the terms of
the English language translation shall control. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 27 

 Confidential 
  

 12.12 Notices and Deliveries. Any notice or other communication required or permitted
hereunder shall be in writing and shall be deemed given (a) when delivered personally, (b) three (3) Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (c) one
(1) day after deposit with a commercial express courier specifying next day delivery, with written verification or receipt, as follows: 
  

			
	 If to Antigenics MA, to:
	  	Antigenics, Inc.
		  	 3 Forbes Road

		  	 Lexington MA 02421 U.S.A.

		  	 Attention: Vice President, Business Development

		
	 with copy to:
	  	 Antigenics, Inc.

		  	 3 Forbes Road

		  	 Lexington MA 02421 U.S.A.

		  	 Attention: Legal Department

		
	 If to GSK, to:
	  	 GlaxoSmithKline Biologicals SA

		  	 89 rue de l’Institut

		  	 B-1330 Rixensart, BELGIUM

		  	 Attention: President and General Manager

		
	 with a copy to:
	  	 GlaxoSmithKline Biologicals SA

		  	 89 rue de l’Institut

		  	 B-1330 Rixensart, BELGIUM

		  	 Attention: Legal Department

 However, all invoices shall be sent by Antigenics MA to GSK’s Licensing Manager, Account Department,
GlaxoSmithKline Biologicals SA, 89 rue de l’Institut, B-1330 Rixensart, Belgium or at such other address GSK may later designate in writing. 
 12.13 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank.] 
  

 28 

 Confidential 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be signed by their respective
corporate officers, duly authorized as of the day and year first above written. 
 Antigenics, Inc., a Massachusetts corporation and wholly owned subsidiary
of Antigenics, Inc., a Delaware corporation 
  

			
	 By:
	 	/s/ P.Thornton
		
	 Name:
	 	Peter Thornton
		
	 Title:
	 	Chief Financial Officer
	
	 GlaxoSmithKline Biologicals SA

		
	By:	 	/s/ Jean Stephenne
		
	Name:	 	Jean Stephenne
		
	Title:	 	President, General Manager

  

 29 

 Confidential 
  

 Exhibit A 
 Annual Update 
 MAY 2006 – 
 INDICATIVE NON-BINDING DATES 
  

							
	 LICENSED VACCINE
	  	 STATUS
	  	 BLA
	  	 APPROVAL

	 [**]
	  	[**]	  	[**]	  	[**]

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit B 
 Co-exclusive Vaccines 
 For the Prophylaxis or Treatments of: 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit C 
 Exclusive Vaccines 
 For the Prophylaxis or Treatments of: 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit D 
 Non- exclusive Vaccines 
 For the Prophylaxis or Treatments of: 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit E 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit F 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit G 
 Press Release 
 DRAFT, NOT FOR IMMEDIATE RELEASE 
  

			
		  	 Sunny Uberoi
 Media Relations
 917.443.3325
 suberoi@antigenics.com

		
		  	 Shalini Sharp
 Investor Relations
 800.962.2436
 ir@antigenics.com

 ANTIGENICS ANNOUNCES EXPANSION OF ITS LICENSE AND SUPPLY AGREEMENT 
 WITH GLAXOSMITHKLINE BIOLOGICALS FOR QS-21 STIMULON® ADJUVANT 
 Conference Call to be
Held Today at XX ET 
 NEW YORK – July XX, 2006 – Antigenics Inc. (NASDAQ: AGEN) today announced that the company has signed expanded
license and supply agreements for the use of QS-21 Stimulon® adjuvant with GlaxoSmithKline
Biologicals, a vaccine division of GlaxoSmithKline (GSK). QS-21 is a key component included in several of GSK’s proprietary adjuvant systems. A number of GSK’s vaccine candidates currently under development are formulated with GSK’s
proprietary adjuvant systems containing QS-21. 
 Under the terms of the agreements, GSK will purchase a percentage of its QS-21 supply requirements from
Antigenics through 2014. Antigenics will also transfer manufacturing technologies to GSK under the supply agreement. GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a
period of at least 10 years after first commercial sale under the supply agreement. 
 “We are delighted to announce this transaction with
GlaxoSmithKline,” said Garo H. Armen, PhD, chairman and CEO of Antigenics. “GSK is the world’s leading developer of preventive vaccines and novel cancer immunotherapeutics and Antigenics’ QS-21 offers GSK one of the most potent
and widely used immunostimulants in development. These agreements represent an important strategic collaboration for both companies.” 
  

 i 

 Confidential 
  

 About QS-21 
 QS-21 is the leading member of the Stimulon family of adjuvants developed by Antigenics, and has been shown to stimulate both antibody (humoral) as well as cellular immune responses. Published clinical studies have shown QS-21 to be
significantly more effective in stimulating antibody responses than aluminum adjuvants, the only adjuvants used in approved vaccines in the United States today. QS-21 has not only become a critical component in the development of preventative
vaccine formulations across a wide variety of infectious diseases, but may also be essential in enabling a new generation of therapeutic vaccines to treat cancer and degenerative disorders. 
 QS-21–based vaccines are being evaluated in more than 50 different indications through commercial partnerships with pharmaceutical companies, academic institutions
and Antigenics’ internal programs. A number of pharmaceutical and biotechnology companies have licensed QS-21, including GlaxoSmithKline plc, Elan Corporation, plc, Wyeth, Pharmexa A/S and Advanced BioScience Laboratories, Inc. 
 Conference Call Information 
 Antigenics executives will host a
conference call at XXX a.m. ET today. To access the live call, dial XXX (domestic) or XXX (international); the access code is XXX. The call will also be webcast and will be accessible from the company’s website at www.antigenics.com/webcast/. A
replay will be available approximately two hours after the call through midnight ET on XXX. The replay number is XXX (domestic) or XXX (international), and the access code is XXX. The replay will also be available on the company’s website
approximately two hours after the live call. 
 About Antigenics 
 Antigenics is working to develop treatments for cancers, infectious diseases and autoimmune disorders. The company’s investigational product portfolio includes Oncophage® (vitespen), a patient-specific therapeutic cancer vaccine being evaluated in several
indications; AroplatinTM, a liposomal, third-generation platinum chemotherapeutic; ATRA-IV, a liposomal retinoic acid; AG-707, a therapeutic vaccine for the treatment of genital herpes; AU-801, a preclinical program targeting autoimmune
disorders; and QS-21, an adjuvant being evaluated by Antigenics’ corporate partners in several late-stage clinical trials. For more information, please visit www.antigenics.com. 
 [ANTIGENICS WILL INSERT LEGAL DISCLAIMER] 
  

 ii 

 Confidential 
  

 Exhibit H 
 Certain Statements Pre-Approved for Public Disclosure 
  

	 	•	 	A number of pharmaceutical and biotechnology companies have licensed QS-21, including GlaxoSmithKline, Elan Corporation, Wyeth, Pharmexa A/S and Advanced BioScience Laboratories,
Inc. 

  

	 	•	 	Antigenics signed expanded license and supply agreements for the use of QS-21 Stimulon® adjuvant with GlaxoSmithKline. 

  

	 	•	 	QS-21 is a key component included in several of GSK’s proprietary adjuvant systems. 

  

	 	•	 	Several GSK proprietary adjuvant systems containing QS-21 are included in a number of GSK of GSK’s vaccine candidates currently under development. 

  

	 	•	 	Under the terms of the agreements, GSK will purchase a percentage of its QS-21 supply requirements from Antigenics through 2014. 

  

	 	•	 	Antigenics will also transfer manufacturing technologies to GSK under the supply agreement. 

  

	 	•	 	GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for at least 10 years after first commercial sale under
the supply agreement. 

  

 i 

 Confidential 
  

 Exhibit I 
 Current Licensed Patent Rights 
  

											
	 Country
	  	 Serial/Application No.
	  	 Filed
	  	 Title
	  	 Status
	  	 Expiration

	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]
	  	 [**]

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 iMANUFACTURING TECHNOLOGY TRANSFER & SUPPLY AGREEMENT

 Confidential 
 Exhibit 10.2 
 MANUFACTURING TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT 
 BY AND BETWEEN 
 ANTIGENICS, INC., A
MASSACHUSETTS CORPORATION 
 AND 
 GLAXOSMITHKLINE BIOLOGICALS SA 

 Confidential 
  

 MANUFACTURING TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT 
 This Manufacturing Technology Transfer and Supply Agreement (this “Agreement”) is made effective this 6th day of July, 2006
(“Effective Date”) by and between Antigenics Inc., a Massachusetts corporation and wholly owned subsidiary of Antigenics Inc., a Delaware corporation, having offices at 3 Forbes Road, Lexington, MA 02421 (“Antigenics
MA”), and GlaxoSmithKline Biologicals SA, a Belgian company, having an address at 89 rue de l’Institut, 1330 Rixensart, Belgium (“GSK”) (each singularly a “Party” and collectively the
“Parties”). 
 WHEREAS, Antigenics MA and GSK are parties to that certain License, Development, and Supply Agreement entered
into effective September 11, 1992 between Cambridge Biotech Corporation (predecessor to Antigenics MA) and Smithkline Beecham p.l.c. (predecessor to GlaxoSmithKline plc an Affiliate of GSK) (as amended, the “Prior Agreement”);
and 
 WHEREAS, GSK has an interest in gaining certain manufacturing rights for QS-21 and restructuring its partnering arrangement with
Antigenics MA; 
 WHEREAS, Antigenics MA has an interest in expanding its collaborative relationship with GSK; 
 WHEREAS, GSK and Antigenics MA now desire to terminate and supercede the Prior Agreement with this Agreement and the License Agreement (as hereinafter
defined); 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as follows: 
 1. Definitions.

 The following terms, whether used in the singular or the plural, shall have the following meanings for purposes of this Agreement:

 1.1 “Affiliate” means any corporation, firm, partnership or other entity, which controls, is controlled by or is under
common control with a Party. For purposes of this Section 1.1, “control” means direct or indirect ownership of fifty percent (50%) or more, or such lesser percentage which is the maximum allowed to be owned by a foreign
corporation in a particular jurisdiction, of the outstanding stock or other voting rights entitled to elect directors thereof or the ability to otherwise control the management of the corporation, firm, partnership or other entity. 
 1.2 “BMF” means Antigenics MA’s FDA biologics master file(s) for QS-21. 
 1.3 “Business Day” means a day on which banking institutions in both Brussels, Belgium and Boston, Massachusetts are open for business.

  

 1 

 Confidential 
  

 1.4 “cGMP” means the current European Guidelines, ICH Guidelines and United States
Good Manufacturing Practices for Finished Pharmaceuticals pursuant to 21 C.F.R. 210 et seq., as amended from time to time. 
 1.5
“cGMP Consistency Lots” means minimum of [**]commercial grade process validation runs for Antigenics MA’s facility, Manufactured in accordance with the Specifications. 
 1.6 “Completion of the [**]of the [**]” means (a) [**] of all [**] of the [**] by [**] to [**] in accordance with Section [**] and
(b) performance of a [**] in accordance with [**] and [**] of [**] at [**] in accordance with [**] and [**] of [**] at [**] , of one (1) [**] of [**] (which [**] is [**] without any [**] from the [**] which would [**] and [**] of [**]) ,
in accordance with the [**], which [**] shall be [**] the [**] to [**] in [**] with [**], for the [**] of [**] and [**] the [**] of the [**]. For avoidance of doubt, Completion of the [**] of the [**] does not require [**] and [**] of [**].

 1.7 “Confidential Information” has the meaning set forth in Article 9 hereof. 
 1.8 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 
 1.9 “First Commercial Sale” means the date of first commercial sale of a QS-21 Vaccine by GSK or its Affiliates or Third Party
Sublicensees or distributors anywhere in the Territory. 
 1.10 “Fully Burdened Costs” means: (a) in the case where
Antigenics MA Manufactures QS-21 for supply to GSK hereunder, the total cost to Manufacture by Antigenics MA and/or its Affiliates hereunder, which total cost shall include direct and indirect labor costs, direct material costs (including without
limitation, raw materials, lab supplies and other materials used directly in Manufacturing QS-21) and indirect material costs (including without limitation shipping materials (driven by shipments not batches), stability materials, batch record
materials, sundry supplies to support QS-21 Manufacture, record keeping, stationary, incidental supplies etc.) calculated in accordance with Generally Accepted Accounting Principles (“GAAP”), and Other Overhead Costs calculated in
accordance with GAAP [**] 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 2 

 Confidential 
  

 
[**]; or (b) in the case where Antigenics MA engages a Third Party to Manufacture QS-21 on its behalf for supply to GSK hereunder, the actual cost to
Antigenics MA to have QS-21 Manufactured and supplied by such Third Party, including without limitation, direct and indirect costs borne by Antigenics MA for any internal quality assurance, quality control, fill/finish, packaging, shipping, and/or
delivery, in each case as duly documented by Antigenics. For either (a) or (b) above, Fully Burdened Costs shall also include direct and indirect costs incurred by Antigenics MA as a result of Antigenics MA fulfilling its Manufacturing and
supply obligations pursuant to this Agreement, but shall specifically exclude any costs or expenses otherwise payable or reimbursable by GSK hereunder. Antigenics MA’s estimated Fully Burdened Costs under (b) above, based on [**]
Manufacture of a [**] batch of QS-21 for [**], are detailed hereto as Exhibit D attached hereto. Antigenics MA’s estimated Fully Burdened Cost details shall be updated annually (or semi-annually upon the request of GSK) by Antigenics MA
and shall be [**]. 
 1.11 “Gross Sales” has the meaning set forth in Section 1.25 below. 
 1.12 “License Agreement” means the license agreement by and between Antigenics MA and GSK entered into contemporaneously with this
Agreement and providing GSK with license rights under certain intellectual property to use QS-21 (as defined below) to develop, make, have made, use, sell, offer for sale and import certain products containing QS-21. 
 1.13 “Licensed Indications” means the Vaccine indications licensed to GSK pursuant to the License Agreement. 
 1.14 “Licensed Vaccines” means the Vaccines for which GSK has license rights under the License Agreement. 
 1.15 “Manufacture or Manufacturing” means the storage, production, purification, handling, materials procurement, processing, testing,
packaging and release of QS-21 in accordance with this Agreement. 
 1.16 “Manufacturing Capacity” means Antigenics
MA’s or its Affiliates or authorized Third Party manufacturer’s capacity for QS-21 Manufacture for [**] and [**] as set forth on Exhibit C attached hereto and incorporated herein, or such higher capacity as Antigenics MA may advise
GSK from time to time in writing. 
 1.17 “Manufacturing Improvements” means any development, enhancement, improvement,
invention, modification, or derivative (whether or not patentable) necessary for or actually applied to the Manufacture of QS-21 that is made, discovered, conceived or reduced to practice by or on behalf of GSK or its Affiliates in the course of the
further development or Manufacturing of QS-21 at any time during the [**] of this Agreement or by Antigenics MA or its Affiliates in the course of the further 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 3 

 Confidential 
  

 
development or Manufacture of QS-21 at any time during the [**] of this Agreement. For the avoidance of doubt, Manufacturing Improvements specifically
exclude any development, enhancement, improvement, invention, modification, or derivative (whether or not patentable) relating to [**] (as opposed to [**]) or [**] or [**] or [**] of [**] with a [**] other [**] or any other [**] of a [**].

 1.18 “Manufacturing Technology” means (i) United States Patent No. [**] (the “[**] Patent”),
together with any patents issuing from any continuations, continuations-in-part (to the extent that the claims therein are directed to subject matter disclosed in the [**] Patent), divisionals, substitutions, reissues, reexaminations or extensions
of the [**] Patent, and any foreign counterparts or equivalents of the foregoing, and (ii) the technical and regulatory information contained in the Manufacturing Technology Package, and (iii) any know-how owned or controlled by Antigenics
MA (with the right to grant licenses or sublicenses hereunder) existing as of the Effective Date that are necessary or reasonably useful for the Manufacture of QS-21 and (iv) any Manufacturing Improvements owned or controlled by Antigenics MA
or its Affiliates (with the right to grant licenses or sublicenses hereunder) whether or not claimed by a patent filed by Antigenics MA. 
 1.19 “Manufacturing Technology Package” means all relevant technical and regulatory information on QS-21 and the QS-21 Manufacturing process owned and/or controlled by Antigenics MA (with the right to transfer to GSK BIO),
as listed under the heading “Phase 1: Transfer of Enabling Technology (Manufacturing Technology Package)” in the Manufacturing Technology Transfer Plan. 
 1.20 “Manufacturing Technology Transfer Royalty” has the meaning set forth in Section 5.3 hereof. 
 1.21 “Manufacturing Technology Transfer Plan” means the written transfer plan agreed to between and signed by both Parties contemporaneously with this Agreement, which forms an integral part hereof,
which will set forth the activities of each Party relating to the transfer of the Manufacturing Technology to GSK and the objectives, criteria, milestones and timelines relating to each Party’s Manufacturing activities hereunder including
without limitation, cooperation of the Parties to ensure [**] between the Parties and timelines for [**] of [**] as further described therein, and as may be updated from time to time until completion of all contemplated activities. 
 1.22 “Manufacturing Transition Date” means January 1, 2012, unless another date is agreed to between the Parties for GSK to begin
Manufacturing itself in accordance with Section 2.5 and 3.2 (the “Manufacturing Transition Date”). 
 1.23
“Marketing Approval” means approval received from the FDA or any comparable approval in any non-US jurisdiction with any relevant Regulatory Authority granting the right to commercialize QS-21 Vaccines (but specifically independent
of pricing or reimbursement considerations, where applicable). 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 4 

 Confidential 
  

 1.24 “Minimum Purchase Requirement” has the meaning set forth in Section 3.4(a)
hereof. 
 1.25 “Net Sales” means the amount billed or invoiced on arms length sales of QS-21 Vaccines by GSK, its
Affiliates or Third Party Sublicensees to Third Parties including its distributors (“Gross Sales”) less deductions duly documented for (i) normal and customary trade, quantity and cash discounts and non-affiliated
broker’s, distributor’s or agent’s commissions actually allowed and taken; (ii) amounts repaid or credited by reason of rejection or return or retroactive price reduction; (iii) to the extent separately stated on purchase or
sales orders, invoices, or other documents of sale, sales and excise taxes and duties levied on and/or other governmental charges made as to production, sale, importation, transportation, delivery or use paid by or on behalf of GSK or its Affiliates
or Third Party Sublicensees; (iv) transportation costs including insurance; and (v) the [**] determined as [**] of [**] and other special [**] and/or [**] and [**] with Licensed Vaccines; (vi) any [**] to [**] on [**], provided
however that [**] under [**] shall not exceed [**] of [**]; and (vii) contributions and payments required by the [**] to be made pursuant to the [**], specifically with respect to any of [**], and which [**] and [**] have been [**] on to the
[**] and are [**] in the [**] of [**] and which are not [**], provided however that deductions under this subparagraph (vii) and subparagraph (v) shall not exceed [**] of [**] in the [**]. Sales between or among GSK and its Affiliates or
Third Party Sublicensees shall be excluded from the computation of Net Sales except where the Affiliates or Third Party Sublicensees are end users, but Net Sales shall include the subsequent final sales to Third Parties by the Affiliates or Third
Party Sublicensees. 
 For the avoidance of doubt, in the event GSK gets any indirect financial interest, income or other consideration back from the
subsequent QS-21 Vaccines sales of GSK distributors to Third Parties, such financial interest, income or consideration shall be included as Net Sales. In addition, in the event that GSK has entered into a distribution agreement with a Third Party
and which distribution agreement is in a form that is in economic and business substance a sublicense relationship and not a traditional distribution relationship in such country or countries, then such distributor shall be treated as a Sublicensee
for purposes of calculating Net Sales and royalties hereunder. 
 If GSK or any of its Affiliates or Third Party Sublicensees makes any transfer of QS-21
Vaccines to Third Parties for consideration other than monetary value or as part of a multi-product transaction, such transfer will be considered a sale hereunder for Net Sales, accounting and royalty purposes. Net Sales for any such transfers will
be determined on a country by country basis and will be the average price of “arms length” sales of QS-21 Vaccines by GSK or its Affiliates or Third Party Sublicensees s in such country during the 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 5 

 Confidential 
  

 
royalty reporting period in which such transfer occurs or, if no such “arms length” sales occurred in such country during such period, during the
last period in which such “arms length” sales occurred. If no “arms length” sales have occurred in a particular country, Net Sales for any such transfer in such country will be the average price of “arms length” sales
of QS-21 Vaccines in all countries in the Territory by GSK, its Affiliates or Third Party Sublicensees. 
 If QS-21 Vaccine(s) is (are) sold as part of a
Combination Vaccine (as hereinafter defined), Net Sales for purposes of determining royalties on QS-21 Vaccine(s) in the Combination Vaccine shall be calculated by [**] of the [**] (as determined in accordance with the provisions of this Section) by
the [**], where [**] is the [**] of the QS-21 Vaccine(s) [**] in the [**] and [**]) and [**] is the [**] of the [**] in the [**] in the [**] and [**]). 
 As
used herein, “Combination Vaccine” means QS-21 Vaccines formulated in combination with one or more Other Vaccine Product(s). As used herein, “Other Vaccine Product” means a vaccine product, other than a QS-21
Vaccine, which is [**] with [**] and [**] when [**] with the [**], as [**] by [**] to [**]. 
 In the event that no such separate sales are made of the QS-21
Vaccine or Other Vaccine Product(s) in such Combination Vaccine in the relevant country during the royalty period in question, then by [**] of the [**] (as determined in accordance with the provisions of this Section) by the [**], where [**] is the
[**] of the [**] in [**] within the [**] and [**], and [**] is the [**] of the [**] in such [**] within the [**] and [**]. 
 In the event that no such
separate sales are made of the QS-21 Vaccines or any of the Other Vaccine Products in such Combination Vaccine in the relevant countries within the same geographical region and similar economic profile during the royalty period in question, Net
Sales, for the purposes of determining royalty payments, shall be calculated as [**] in [**] the [**], provided that in the event the Parties are [**] to [**] to [**] on [**] after [**], then [**] shall be [**] for [**] to an [**] to the [**] shall
be [**]. 
 1.26 “Other Costs” means the costs incurred and paid by Antigenics MA and/or its Affiliates for the execution of
the Manufacturing Technology Transfer Plan, activities under [**] hereof, and related activities, as such costs shall be set forth in an “Other Costs Budget” to be established and agreed by the Steering Committee within [**] after the
execution of this Agreement, and which shall include without limitation: (i) the direct and indirect labor costs (including personnel time of Antigenics 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 6 

 Confidential 
  

 
MA’s or its Affiliates’ employees (charged at an FTE rate of [**]), and any consultation services or cooperation charged [**], provided by or on
behalf of Antigenics MA or its Affiliates in accordance with the Manufacturing Technology Transfer Plan and (ii) direct and indirect material costs. Other Costs specifically excludes Antigenics MA’s Fully Burdened Costs of Manufacturing
QS-21 Vaccine otherwise chargeable to GSK under this Agreement. 
 1.27 “Other Overhead Costs” for purposes of determining
Fully Burdened Costs, means appropriate [**] and [**] of [**] related to QS-21 Manufacturing activities. 
 1.28 “Quality
Agreement” means the Quality Agreement entered into between the Parties contemporaneously with this Agreement, as may be revised by the Parties from time to time and which forms an integral part hereof. 
 1.29 “QS-21” means a substantially pure saponin adjuvant isolated from crude Quillaja saponaria tree extract and referred to as
QS-21, a Stimulon® adjuvant. 
 1.30 “QS-21 Vaccine(s)” means, during the term of the License Agreement, the Licensed Vaccines, and after expiration of a Valid Claim of
the Licensed Patent Rights covering the applicable Vaccine product, QS-21 Vaccines means any Vaccine product of GSK or its Affiliates or Third Party Sublicensees formulated using QS-21. 
 1.31 “Regulatory Authority” means the U.S. or foreign government agency or health authority that regulates and grants recommendations
for approvals for the manufacture and sale of pharmaceutical products. 
 1.32 “Release” has the meaning set forth in
Section 4.1 hereof. 
 1.33 “Specifications” means the applicable release specifications for QS-21 agreed to by the
Parties and set out in Exhibit A attached hereto and incorporated herein, as may be amended from time to time by mutual agreement of the Parties. 
 1.34 “Steering Committee” means the Steering Committee established in accordance with this Agreement. 
 1.35 “Sublicensee” means any Affiliate or Third Party to whom GSK grants a sublicense of any of the license rights granted to GSK pursuant to the terms and conditions of the License Agreement.

 1.36 “Term” has the meaning set forth in Section 8.1 hereof. 
 1.37 “Territory” means the world. 
 1.38 “Third Party” means any entity other than the Parties to this Agreement or their respective Affiliates. 
 1.39 “Vaccine” means a preparation in finished form (not requiring any further processing or packaging prior to sale to the end user). 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 7 

 Confidential 
  

 2. Steering Committee, Manufacturing Technology Transfer, Cooperation and License Rights. 
 2.1 General. Antigenics MA will transfer the Manufacturing Technology Package to GSK in accordance with the Manufacturing Technology Transfer
Plan, and both Parties will perform their respective activities under and in accordance with the Manufacturing Technology Transfer Plan in order to facilitate [**] between the two Parties. 
 2.2 Steering Committee. 
 (a) As soon as reasonably practicable after the Effective Date, Antigenics MA and GSK BIO will establish a steering committee (the “Steering Committee”), to oversee the activities to be undertaken pursuant to this
Agreement. The Steering Committee will facilitate communication between the Parties and provide a forum to review any technology transfer, supply and manufacturing matters pertaining to QS-21. The Steering Committee shall consist of three
(3) individuals appointed by each Party or such other number of representatives the Parties may mutually agree upon and may also include additional representatives from the Parties, as mutually agreed, on an ad-hoc basis and shall be co-chaired
by GSK and Antigenics MA. The co-chairs will coordinate agendas and minute-taking for meetings of the Steering Committee. Each Party may replace its Steering Committee representatives at any time upon written notice to the other Party provided that,
in the [**] and will [**] to any [**]. The Steering Committee may establish certain ad hoc sub-committees which consider certain matters, including without limitation, one or more sub-committees (consisting of at least one (1) individual from
each Party) to address (i) technical matters in dispute that have not been resolved under the Quality Agreement and (ii) repetitive, specific cGMP issues. 
 (b) The Steering Committee shall meet (in person, or by teleconference or videoconference as agreed by the Parties) at least [**] during
the first [**] and thereafter [**] (or more frequently as the Parties mutually agree is appropriate, or as determined by [**] during any period of Antigenics MA’s inability to supply under Section 3.5(c), on such dates and at such times as
the Parties shall agree. The Steering Committee (itself or through one or more sub-committes as contemplated in Section 2.2(a) above) will, among other things (i) oversee the Manufacturing Technology transfer; (ii) review and manage
the Manufacturing relationship hereunder, including without limitation, review the Manufacturing requirements for QS-21 for GSK, (iii) discuss and review for Antigenics MA’s reasonable consideration, the [**], discuss 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 8 

 Confidential 
  

 
and review validation plans for Manufacturing, QC testing and facilities, and coordinate efforts to ensure [**] between the two Parties; (iv) establish
the Other Costs Budget as described in Section 1.26 above), and (v) address such other matters as may be agreed to between the Parties including open matters that may exist at the level of the sub-committees. All information provided to
Antigenics MA pursuant to this Section shall be considered the Confidential Information of GSK in accordance with Article 9; provided, however, that GSK grants permission to Antigenics MA to (i) disclose such information as may be
necessary or reasonably useful to comply with any applicable laws, rules, regulations, or guidelines, including to reference and submit any such information to the FDA and other relevant Regulatory Authorities and for inclusion in the QS-21 BMF or
comparable filing, subject to GSK’s confidential obligations to Third Parties. All information provided to GSK pursuant to this Section shall be considered the Confidential Information of Antigenics MA in accordance with Article 9, provided
however that Antigenics MA grants permission to GSK to disclose such information as may be necessary or reasonably useful to comply with any applicable laws, rules, regulations, or guidelines, including to reference and submit any such
information to the FDA and other relevant Regulatory Authorities and for securing product license applications with respect to QS-21 Vaccines, subject to Antigenics MA’s confidential obligations to Third Parties. 
 (c) Subject to Section 10.1 below, the Steering Committee will operate by consensus, and each Party will consider the other
Party’s input in good faith, provided however that [**] shall [**] in [**] on the [**] with [**] with respect to [**], provided that (x) [**] shall not [**] in [**] that [**] in [**] to a [**] or other [**], or [**] in [**] between [**]
and [**] or [**] hereunder); and (y) without in any way limiting (x), GSK shall indemnify and hold harmless Antigenics MA from any liability incurred by Antigenics MA as a result of [**]. 
 2.3 Manufacturing Technology Transfer Plan, Manufacturing Technology Transfer Team and Manufacturing Technology Package. 
 (a) Manufacturing Technology Transfer Plan. Antigenics MA will use commercially reasonable efforts to execute the Manufacturing
Technology Transfer Plan (and to [**] to execute its activities under the Manufacturing Technology Transfer Plan), in an efficient and timely manner and in accordance with schedule as set forth in the Manufacturing Technology Transfer Plan. In
particular, Antigenics MA will [**] under the Manufacturing Technology Transfer Package (other than the [**]) within [**] after the Effective Date and the Parties shall use commercially reasonable efforts to complete the Phase 1 of the Manufacturing
Technology Transfer Plan with the goal of reaching Completion of the Transfer of the Manufacturing Technology Package by the later of [**] or [**]. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 9 

 Confidential 
  

 (b) Establishment of Manufacturing Technology Transfer Team. As soon as
practicable after the Effective Date and until completion of the Manufacturing Technology Transfer Plan, GSK and Antigenics MA shall establish a Manufacturing Technology Transfer Team comprised at least of four (4) representatives designated by
GSK and at least four (4) representatives designated by Antigenics MA; provided that GSK and Antigenics MA may designate an equal number of additional representatives from time to time. Each Party shall make its initial designation of
its representatives not later than [**] after the Effective Date. Either Party may change its designees to the Manufacturing Technology Team at any time upon written notice to the other Party. Each representative shall have appropriate skills and
competencies for its role on the team. 
 (c) Contact Persons. The Parties will identify contact persons to serve as
the primary contacts for and day-to-day management of the coordination, delivery and receipt of the Manufacturing Technology under the Manufacturing Technology Transfer Plan. 
 (d) Transfer of the Manufacturing Technology Package. Antigenics MA shall notify GSK in writing of the Completion of the Transfer
of the Manufacturing Technology Package, and provide reasonable evidence of such completion in accordance with any delivery criteria set forth in the Manufacturing Technology Transfer Plan, which shall constitute reasonable evidence for the purpose
of determining whether the transfer is complete. GSK shall have [**] to either agree upon the Completion of the Transfer of the Manufacturing Technology Package and in that case GSK shall [**] described in [**] in accordance with the provisions of
[**] or identify any deficiencies, and in the latter case shall promptly provide Antigenics MA with written notice thereof and the Parties shall promptly discuss such issue. Each Party shall use reasonable efforts, if applicable, to timely address
any such deficiencies that were specified in writing. Upon correction of such noticed failures, Antigenics MA shall notify GSK BIO in writing. In the event of any disagreement of the Parties regarding the Completion of the Transfer of the
Manufacturing Technology Package by Antigenics MA, the matter shall be referred to the Steering Committee for resolution. If the Steering Committee is unable to resolve the matter within [**] of such referral, the matter shall be resolved in
accordance with the dispute resolution provisions in Section 10.1 hereof. In any case, [**] shall only be [**] described in [**] upon resolution of the Completion of the Transfer of the Manufacturing Technology Package issue either [**] or as
will be decided under Section 10.1 hereof. 
 (e) Other Costs. GSK BIO shall reimburse Antigenics MA monthly for
the Other Costs incurred by Antigenics MA in accordance with the Other Costs Budget to be established by the Steering Committee, within [**] of receipt of duly documented invoices from Antigenics MA. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 10 

 Confidential 
  

 2.4 Regulatory Cooperation. 
 (a) Access to Regulatory Documents and Communications. GSK will have the right to cross-reference the BMF. As part of the
Manufacturing Technology Transfer Plan, Antigenics MA shall provide GSK with a redacted copy of the BMF. In addition, each Party shall promptly send the other Party a copy of any material notices, material reports, and other material communications
it has received from any Regulatory Authority or other governmental entity concerning QS-21. Antigenics MA will discuss with GSK any material documents relating to Manufacturing matters for the QS-21 Vaccines pertaining to the QS-21 that Antigenics
MA receives from, or intends to submit to the Regulatory Authorities in the Territory in line with Section 5.8 of the License Agreement and GSK will discuss with Antigenics MA any material documents relating to Manufacturing matters for the
QS-21 Vaccines pertaining to the QS-21 that GSK receives from, or intends to submit to the Regulatory Authorities in the Territory in line with Section 5.8 of the License Agreement but only to the extent these documents relate to the subject
matter described in Section 2.2 (c) (x) above. Upon GSK’s reasonable request, Antigenics MA will provide GSK with regulatory support as reasonably necessary for development and licensure of GSK QS-21 Vaccines. Likewise, upon
GSK’s reasonable request, Antigenics MA will reasonably cooperate with GSK in support of all regulatory filings involving QS-21, including participation in meetings with Regulatory Authorities as appropriate. In addition, Antigenics MA will
authorize and reasonably cooperate with GSK to prepare any visit or inspection requested by Regulatory Authorities. 
 (b)
Changes to Manufacturing Processes. Any changes to Manufacturing processes shall be handled pursuant to the provisions of the Quality Agreement and Section 2.8 of this Agreement. 
 (c) Adverse Events Reporting. GSK shall be responsible for reporting all safety related events from studies of QS-21 Vaccines to
the appropriate Regulatory Authorities and agencies according to the applicable local regulations, including without limitation, the regulations outlined in 21 CFR 312.32 (and other applicable international regulations). GSK and Antigenics MA shall
keep each other informed of any serious adverse reactions, or other significant, unusual or unexpected safety findings related to QS-21 as provided for in Section 5.8 of the License Agreement. 
 (d) Compliance. Notwithstanding the foregoing and for the avoidance of doubt, (i) GSK shall comply, and shall cause its
Sublicensees to comply, with all applicable federal and state laws, rules, regulations and guidelines in connection with its performance under this Agreement and the development and commercialization of QS-21 Vaccines; and (ii) Antigenics MA
shall comply, and shall cause its Affiliates and Third Party Manufacturer (other than the contract manufacturer selected by the Steering Committee, whose compliance shall be the joint responsibility of Antigenics MA and GSK) to comply, with the
Specifications, the cGMP and other applicable federal and State laws, rules and regulations in connection with its performance under this Agreement and the Manufacture of QS-21. Without limiting the generality of the foregoing, GSK shall use
Commercially Reasonable Efforts (as such term is defined in the License Agreement) to ensure compliance with all applicable product safety, product 

  

 11 

 Confidential 
  

 
testing, product labeling, package marking, and product advertising laws and regulations and International Conference on Harmonisation (ICH) Guidelines. GSK
shall be solely responsible for diligently obtaining all required and/or necessary Regulatory Authority authorizations and approvals to develop, Manufacture and commercialize QS-21 Vaccines hereunder and under the License Agreement. 
 (e) Product Recalls. Any products recalls will be handled pursuant to the terms of the Quality Agreement. 
 2.5 License Grant to GSK. 
 (a) Subject to the terms and conditions of this Agreement (including without limitation, the provisions of Article 4 below and the retained rights of Antigenics MA set forth in Sections 3.1 and 3.2 below), Antigenics MA hereby grants to GSK
a [**] right and license (with the right to grant sublicenses to its Affiliates and Sublicensees as defined in the License Agreement, subject to the provisions of Section 2.5(c) below) to [**] for the sole purpose of [**]. To the extent that
Antigenics MA subcontracts or sublicenses with its Affiliates or Third Parties to Manufacture hereunder, Antigenics MA shall obtain the right under the intellectual property rights of such Affiliate or Third Party related to the Manufacture of
QS-21, with the right to grant sublicenses to GSK and its Affiliates (and such license shall be further sublicensable by GSK to its Affiliates and Sublicensees, subject to the provisions of Section 2.5(c) below), to use any such intellectual
property necessary for or actually applied to the Manufacture of QS-21 that is discovered or developed by such Affiliate or Third Party to preserve the license granted to GSK and its Affiliates in this Section. 
 (b) Notwithstanding the provisions of Section 2.5(a) above, Antigenics MA hereby retains the right and has the obligation to
Manufacture QS-21 for GSK, its Affiliates, and Sublicensees (subject to Section 2.5(c) below), as set forth in Sections 3.1, 3.2 and 3.3 below. For the avoidance of doubt, nothing in this Section 2.5 shall be construed to prevent
Antigenics MA from Manufacturing or having Manufactured QS-21 for itself or any other parties. For the Term of this Agreement, GSK agrees to Manufacture or have Manufactured QS-21 solely in accordance with this Agreement, and for the term of the
License Agreement and thereafter to use QS-21 solely to develop, make, have made, use, sell, offer for sale and import QS-21 Vaccines. 
 (c) GSK may grant sublicenses to Sublicensees provided that: 
 (i) the Sublicensee will
practice the Manufacturing Technology only to the extent granted to GSK under this Agreement; 
 (ii) GSK and each Affiliate
Sublicensee will sign a [**] under which the Affiliate Sublicensee will agree to be bound by the terms of this Agreement; 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 12 

 Confidential 
  

 (iii) GSK and each Third Party Sublicensee shall enter into a written agreement
subject to, consistent with, and not to extend beyond the scope of GSK’s rights under, and the terms and conditions of, this Agreement, or provide for Sublicensee obligations inconsistent with or less than GSK’s obligations under this
Agreement, and which written agreement shall require the Third Party Sublicensee to agree to be bound by and comply with provisions that are consistent with the provisions of this Agreement; 
 (iv) each such side letter or sublicense agreement shall require the Affiliate and/or Third Party Sublicensee, at the election of
Antigenics MA (to be made by Antigenics MA upon notice from GSK at the time the side letter or sublicense agreement is entered into) to either (i)[**] to [**] by the [**] and [**] of, and the [**] of [**] under, [**] or (ii) [**] a [**] within
a reasonable time after the [**] of the [**] , pursuant to which the [**] shall be [**] to [**] from [**] , or a [**] (either [**] or [**] as may be agreed to by Antigenics MA) [**] of [**] and [**] or [**] will [**] such [**] (subject to [**]),
provided that [**], any [**] shall [**]; 
 (v) GSK shall remain responsible for compliance by any Sublicensee receiving a
sublicense hereunder with all terms and conditions of this Agreement relevant to such Sublicensee. GSK shall promptly provide Antigenics MA with a copy of the relevant provisions of such agreement entered into with any Third Party Sublicensee
redacted as may be deemed appropriate by GSK for confidentiality or legal reason; and 
 (vi) in addition and notwithstanding
the foregoing, GSK may grant sublicenses to Affiliate subsidiaries controlled by GSK without entering into a written [**] or sublicense agreement with such subsidiaries, provided that GSK shall and hereby guarantees and remains primarily responsible
for the performance of such subsidiaries in accordance with this Agreement. 
 Should this Agreement terminate for any reason, at GSK’s request (or
Antigenics MA’s election in the event this Agreement and the licenses granted to GSK hereunder are terminated by Antigenics MA for GSK’s material breach in accordance with Section 8.4(c)), and provided that GSK’s Third Party
Sublicensee continues to comply with the provisions of the written agreement to be entered into pursuant to this Section, the Third Party Sublicense shall survive, provided that Antigenics MA shall be substituted for GSK and become the direct
licensor of GSK’s Third Party Sublicensee, provided that Antigenics MA has approved or has not reasonably objected to such written agreement. However, Antigenics MA shall assume no obligations of GSK under such written agreement, other than the
obligation to grant the Manufacturing rights contemplated in this Section 2.5, unless Antigenics MA otherwise agrees. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 13 

 Confidential 
  

 2.6 License Grant to Antigenics MA. Subject to the terms and conditions of this Agreement, GSK
shall grant and hereby grants to Antigenics MA and its Affiliates a [**], right and license, with the right to grant sublicenses, to any [**] (whether or not patented or patentable) to make or have made QS-21. For the avoidance of doubt, nothing in
this Section 2.6 shall be construed as granting Antigenics MA any right to [**] or any right to [**] or to [**]. To the extent that GSK subcontracts or sublicenses with its Affiliates or Third Parties for the performance of GSK’s rights or
obligations hereunder in accordance with this Agreement, GSK shall obtain the right under the intellectual property rights of such Affiliate or Third Party related to the Manufacture of QS-21, with the right to grant sublicenses to Antigenics MA and
its Affiliates (and such license shall be further sublicensable by Antigenics MA), to use any such intellectual property necessary for or actually applied to [**] that is discovered or developed by such Affiliate or Third Party to preserve the
license granted to Antigenics MA and its Affiliates in this Section. 
 2.7 No Other Rights. Except for the express licenses granted
pursuant to this Article 2, no license, express or implied, is granted by either Party to the other Party under any intellectual property or other rights owned or controlled by such Party pursuant to this Agreement. 
 2.8 Disclosure of Manufacturing Improvements. For the avoidance of doubt, no obligations on either Party to disclose Manufacturing Technology are
implied by the license grants set forth herein, and the only Manufacturing Technology disclosure obligations under this Agreement are the specific disclosure and reporting obligations expressly set forth in this Agreement, the Quality Agreement or
the Manufacturing Technology Transfer Plan. The Parties agree that each Party will promptly disclose to the other Party those Manufacturing Improvements that are modifications, improvements or other changes to the Manufacturing process that may
reasonably affect the yield, scale, cost or efficiency of the Manufacturing process, and shall cooperate with the other Party to enable the other Party to practice such modifications, improvements or other changes in its Manufacturing processes in
accordance with such other Party’s rights under this Agreement. 
 3. Manufacture and Supply by Antigenics MA. 
 3.1 Initial Supply. Subject to the terms and conditions contained in this Agreement, until the Manufacturing Transition Date, GSK agrees to
purchase solely from Antigenics MA or it Affiliates (or a Third Party manufacturer approved by GSK, such approval not to be unreasonably withheld or delayed), and Antigenics MA or its Affiliates (or a Third Party manufacturer approved by GSK, such
approval not to be unreasonably withheld or delayed) agrees to supply GSK and its Sublicensees with one hundred percent (100%) of their initial requirements of QS-21 (subject to the Manufacturing Capacity) for use solely in the development,
marketing and sale of QS-21 Vaccines in the Territory. In the event that GSK’s requirements for QS-21 exceed the Manufacturing Capacity, the Parties will work together to increase the Manufacturing 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 14 

 Confidential 
  

 
Capacity as set forth in Exhibit C. Antigenics MA shall use commercially reasonable efforts to Manufacture and supply Commercial Grade cGMP quality of QS-21
(in accordance with Specifications of Exhibit A with a target of [**]) no later than [**], provided that GSK shall reasonably cooperate with Antigenics MA to that end in accordance with Antigenics MA reasonable request and reasonable
timeline. Thereafter, Antigenics MA will only supply Commercial Grade cGMP QS-21 to GSK. 
 3.2 Future Supply. Commencing on the
Manufacturing Transition Date and subject to the terms and conditions contained in this Agreement, GSK agrees to purchase solely from Antigenics MA or its Affiliates (or a Third Party manufacturer approved by GSK, such approval not to be
unreasonably withheld or delayed), and Antigenics MA (itself or through an Affiliate or a Third Party manufacturer approved by GSK, such approval not to be unreasonably withheld or delayed) retains the right and has the obligation, to Manufacture,
[**] percent [**] of GSK’s and its Affiliates and, if requested by GSK in accordance with this Agreement, Third Party Sublicensees’ requirements of QS-21 (subject to the Manufacturing Capacity) for use solely in the development, marketing
and sale of QS-21 Vaccines in the Territory, up to [**] per year for three (3) years after the Manufacturing Transition Date. In the event that GSK’s requirements for QS-21 exceed [**] per year during such three year period, the Parties
will discuss in good faith the potential for increasing the [**] cap hereunder. Beyond that period, at either Party’s request, the Parties will discuss in good faith, the possibility of extending the QS-21 supply by Antigenics MA to GSK.

 3.3 Supply to GSK’s Sublicensees. Prior to supplying any Sublicensee under the License Agreement with QS-21 supplied to GSK
hereunder, GSK shall enter into a written agreement with such Sublicensee pursuant to which such Sublicensee acknowledges and agrees to be subject and subordinate to the provisions of this Agreement (but specifically excluding the right of such
Sublicensee to Manufacture or have Third Parties Manufacture QS-21 prior to [**]). In accordance with Section [**], Antigenics MA may [**]. 
 3.4 Forecasts and Purchase Orders. GSK shall issue forecasts and firm purchase orders for its requirements of QS-21 as follows: 
 (a) Annual Forecasts. Attached hereto as Exhibit B and incorporated herein is GSK’s indicative forecasts of the quantity of QS-21 it expects to require for 2006- 2014 in a form substantially similar
to the table included in Exhibit B-1 attached hereto. These long-term forecasts shall be updated by GSK no later than [**] of each year for the remaining years under this Agreement. GSK shall be obligated to order within the immediately following
calendar year not less than [**] percent [**] of the quantity of QS-21 specified in the forecast provided in accordance with the foregoing sentence, and in no event less that the purchase requirement set forth in Sections 3.1 or 3.2 above (as
applicable) (the “Minimum Purchase Requirement”). In the 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 15 

 Confidential 
  

 
event that GSK does not comply with the foregoing provisions of this Section 3.4(a) and delays providing its annual forecast by [**] of a particular
calendar year, then Antigenics MA shall notify GSK of its failure to provide such forecast, and in the event that GSK does not furnish such forecast within [**] of receipt of such notice, then Antigenics MA retains the right, but not the obligation,
to (i) make the Minimum Purchase Requirement for the immediately following calendar year equal to one hundred percent (100%) of the amount set forth in the last annual forecast received from GSK pursuant to this Section 3.4(a), or
(ii) provide GSK with its estimation of what Antigenics MA believes to be GSK’s minimum purchase requirements for such period, and GSK shall have [**] from receipt thereof to provide an update of this estimate. 
 (b) Rolling Forecasts. Not later than the first day of each calendar quarter, GSK shall provide Antigenics MA with a rolling
quarterly forecast of the quantity of QS-21 that it expects to require and purchase from Antigenics MA for the following next [**] calendar quarters, which shall be no less than its Minimum Purchase Requirement (as defined above), and shall be
binding on GSK for hundred percent (100%) as to the first [**] quarters, be binding on GSK for [**] of the quantities of QS-21 forecasted for the next [**] quarters, and be non-binding on GSK as to the remaining [**] calendar quarters. In the
event that GSK does not comply with the provisions of this Section 3.4(b) and fails or delays to provide its forecasts hereunder, then Antigenics MA will notify GSK and GSK shall have [**] to comply with its obligations, otherwise Antigenics MA
may elect to fill the purchase order(s) to be placed in accordance with Section 3.4(c) below for any of the quarters of the concerned forecast, but is not obligated to do so. 
 (c) Firm Purchase Orders. Not later than [**] prior to the beginning of [**], GSK shall provide Antigenics MA with a firm purchase
order for the quantity of QS-21 it intends to purchase hereunder during such [**]. Each firm purchase order shall specify the quantity of QS-21 to be ordered. Such firm purchase order commits GSK to purchase [**] percent [**] of the quantity of
QS-21 set forth in the purchase order during that [**]. In the event that GSK does not comply with the foregoing provisions of this Section and delays ordering or does not submit a purchase order for a particular [**] in a given [**], then
Antigenics MA may notify GSK and GSK shall have [**] to comply with its purchase order obligations (and Antigenics MA shall have an additional [**] to supply GSK beyond the period specified in Section 3.4(d) below). In case of GSK’s
failure to do so, Antigenics MA retains the right to deliver to, and charge GSK for, QS-21 in such [**] in the amount equal to [**], where A equals the [**] for the applicable [**], B equals the [**], and C equals the number of [**] (including the
[**] at issue). 
 (d) Delivery. Antigenics MA shall deliver within [**] of the applicable [**] (the
“Contractual Delivery Date”), and in accordance with 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 16 

 Confidential 
  

 
the Specifications,[**] of the quantity of QS-21 set forth in the applicable firm purchase order (subject to the Manufacturing Capacity) for the
applicable calendar quarter. Such QS-21 shall not [**]; provided, however, that Antigenics MA may make delivery of any firm purchase order that is for less than the Minimum Purchase Requirement, subject to payment by GSK of the [**] of the
[**] up to the [**], and shall have the right to reject that portion of any firm purchase order that exceeds [**] percent [**] of the QS-21 amount set forth in the corresponding last non-binding forecast for that calendar quarter, or any purchase
order that is otherwise inconsistent with the requirements of this Agreement. If Antigenics MA determines that any firm purchase order submitted by GSK, and not rejected by Antigenics MA hereunder, cannot be filled by the Contractual Delivery Date,
including, without limitation, as a result of a supply failure by a Third Party manufacturer, Antigenics MA shall notify GSK in writing promptly upon making such determination. In such case, the Parties will work together, in good faith, to identify
an appropriate resolution to the supply problem. If the Parties cannot reach an agreement on an appropriate resolution to the problem within [**] of bringing this to the attention of the Steering Committee for resolution, then at either Party’s
written request but without prejudice to Section 3.5(c), resolution of the problem will be governed by the [**]. Notwithstanding the foregoing or any other provision of this Agreement, in the event GSK orders QS-21 for any [**] in an amount
greater than [**] percent [**] of the quantity ordered in the firm purchase order for the immediately preceding [**], Antigenics MA will use commercially reasonable efforts to meet the order, but shall be deemed to have met the order if it supplies
by the Contractual Delivery Date [**] percent [**] of the quantities ordered in the firm purchase order for the immediately preceding [**]. In calculating [**] percent [**] of the quantities ordered in firm purchase orders for the [**], the Parties
shall exclude quantities ordered in the preceding [**] in excess of that which Antigenics MA must supply in order to have been deemed to have met the order. Although Antigenics MA may upon request from GSK agree from time to time in its sole
discretion to deliver QS-21 in [**], any such agreement in a given instance shall in no event obligate Antigenics MA to deliver subsequent future orders of QS-21 in any [**] but the [**]. 
 (e) Shipping. Each order of QS-21 shall be shipped F.O.B. Antigenics MA’s facilities (U.C.C. terms) or, in the event
Antigenics MA has a Third Party Manufacture QS-21 in accordance with this Agreement, then at Antigenics MA’s discretion, F.O.B. the Third Party’s facilities. Shipping will be according to the purchase order and to any other specific
written instructions of GSK reasonably acceptable to Antigenics MA or its Third Party manufacturer (or if no written instructions are given, by a common carrier selected by Antigenics MA and reasonably agreeable to GSK, taking into consideration the
specific nature of QS-21). Title to and risk of loss for any order of QS-21 purchased by GSK shall pass to GSK upon the common carrier taking possession and control of the order of QS-21. Unless otherwise agreed to between the Parties, all QS-21
shall be [**]. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 17 

 Confidential 
  

 and in accordance with shipping instructions provided by GSK to Antigenics MA from time to time. 
 (f) All forecasts and purchase orders to be provided by GSK to Antigenics MA hereunder may be transmitted to Antigenics MA via email,
provided that Antigenics MA confirms receipt thereof within [**]. In the event that Antigenics MA does not confirm receipt within [**], GSK shall contact Antigenics MA to ensure that Antigenics MA received such email, or in the alternative, GSK may
provide such forecast or purchase order via the notice requirements of Section 10.12 of this Agreement. 
 3.5 Supply Controls.

 (a) [**]. Without limiting in any way [**] under this Agreement, [**] may [**], either [**] at [**] or [**], to [**]
consistent with the terms of this Agreement. In the event that [**] in connection with Section 3.5(c) below, then [**] will [**] with [**] in its efforts, consistent with the terms of this Agreement. In the event [**] so requests in the future,
the Parties will discuss in good faith the possibility of [**] by such [**] on [**]. 
 (b) [**]. In the event that [**] with
a [**] (other than [**], the [**] (or [**] (either as the [**]), [**] shall be [**] to [**] on [**], and [**] shall [**] to [**]. Such [**] shall [**] shall be an [**] of such [**] thereunder, including with [**]. In addition, each [**] shall [**],
in substance, that, in the event that [**], or any other [**] pursuant to the [**] or any other [**] (collectively, the [**]), shall [**] to [**] or [**] (collectively, [**]) such [**], then the [**] shall (i) timely [**] any and all [**] (if
any) thereunder, pursuant to [**] or any other [**], and (ii) to the extent that [**] effectively [**] the [**] 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 18 

 Confidential 
  

 
[**]. The [**] may [**] such [**] as Antigenics MA and [**] to, [**] the [**] of the [**] prior to [**] of such [**] and provided that such [**] do not [**]
under this Agreement or the [**]. 
 (c) Antigenics MA Inability to Supply. Antigenics MA shall use commercially
reasonable efforts to supply GSK with quantities of QS-21 ordered pursuant to Section 3.3 (c) above. As soon as Antigenics MA determines it will be unable to deliver to GSK the quantities of QS-21 ordered with respect to any particular
calendar quarter, Antigenics MA shall immediately notify GSK, and GSK shall then have the right to secure (whether through [**] or [**]) such quantities of QS-21 that Antigenics MA is unable to fill for the time period that Antigenics MA is unable
to meet such GSK orders [**]. In the event that GSK engages a Third Party to Manufacture as a result of Antigenics MA’s inability to supply hereunder, then Antigenics MA will cooperate with such Third Party in its efforts, consistent with the
terms of this Agreement. 
 4. Antigenics MA Supply. 
 4.1 Documentation with Deliveries. Antigenics MA shall provide, or shall cause any Third Party manufacturer in accordance with this Agreement to provide, to GSK, together with each shipment of QS-21, all
documentation set forth in the Quality Agreement, documenting the quality control authorized release of such shipment in accordance with the terms and conditions of the Quality Agreement (the “Release”). 
 4.2 Testing and Acceptance. GSK shall have [**] days after the delivery to GSK of the order of QS-21 supplied hereunder to determine whether the
QS-21 conforms to the Specifications and order quantity. GSK will be deemed to have acknowledged that an order of QS-21 conforms to the Specifications and order quantity and is accepted, unless GSK rejects the QS-21 order by giving written notice of
non-conformity to Antigenics MA within such [**] day period. If GSK determines that the QS-21 order fails to meet the Specifications, or that there is a shortage in the quantity delivered, it shall promptly so notify Antigenics MA in writing within
such [**] day period. Any such notice shall specify the reason, with supporting documentation, for the non-conformity or the details of any quantity shortage, as the case may be. In the event that Antigenics MA agrees that an order of QS-21 is
non-conforming with the Specifications or that there was a shortage in quantity delivered, Antigenics MA shall, at its own cost (including shipping) use commercially reasonable efforts to replace the non-conforming quantities of QS-21 or make up the
shortage, as soon as reasonably possible. If Antigenics MA does not agree that the particular order of QS-21 fails to meet the Specifications or that it delivered a shortage of QS-21, it shall notify GSK and the Parties (through the Steering
Committee) shall try to negotiate a mutually satisfactory resolution of their differences. Should a dispute over the 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 19 

 Confidential 
  

 
conformity of a QS-21 order persist beyond [**] days after Antigenics MA’s notice to GSK of disagreement, a representative sample of the QS-21 at issue
shall be submitted to an independent testing laboratory designated by GSK and reasonably agreeable to Antigenics MA for testing against the Specifications. The test results obtained from such laboratory shall be final and binding on the Parties. The
cost of such test shall be borne by the Party whose results disagree with those of the independent laboratory. Where the test results demonstrate that the QS-21 order fails to meet any of the Specifications, Antigenics MA shall replace the
non-conforming quantities of QS-21 at no additional cost to GSK as soon as reasonably possible after receipt of such results. The provisions of this Section shall not apply to any QS-21 damaged or lost in transit after delivery by Antigenics MA to
the common carrier, which shall be the responsibility of GSK. 
 4.3 Sample Testing and Records. Sample testing and record retention
shall be in accordance with the Quality Agreement. 
 4.4 Inspections. During the Term of this Agreement, and subject to the last
sentence of this Section 4.4, Antigenics MA shall permit a reasonable number of GSK employees or agents reasonably acceptable to Antigenics MA, as GSK may reasonably from time to time request, at least once a year (and [**] if [**]), access to
Antigenics MA’s QS-21 manufacturing facilities during normal business hours for the purpose of Manufacturing and quality control compliance reviews and inspections (at each Party’s own cost and expense), subject to the remaining provisions
of this Section 4.4. GSK agrees that prior to any such employee or agent visitor entering such QS-21 manufacturing facilities, GSK will provide Antigenics MA with (a) written notice of the visit at least [**] days in advance for routine
annual audits, and (b) reasonable advance notice, and in no event less then [**] notice for [**]. In addition, GSK will obtain from such employees or agents a binding confidentiality agreement in a form acceptable to Antigenics MA in advance of
any visit and that these audits do not take place more often than reasonably necessary. The Parties agree that Antigenics MA may refuse access to or eject any GSK employee or agent if Antigenics MA reasonably believes, and can reasonably demonstrate
to GSK that it has grounds for such belief, that such employee or agent is or may be a security risk to Antigenics MA or does not meet Antigenics MA’s safety or security requirements. Antigenics MA shall have no liability under this Agreement
for refusing access to or ejecting such individual(s). GSK further agrees to protect, defend, indemnify, and hold harmless Antigenics MA and its officers, directors, employees, agents and assignees, from all demands, claims, actions, liability,
loss, damage, costs and expenses including reasonable attorney’s fees, arising out of any claims for personal injury or property damage caused by a GSK employee or agent while visiting such QS-21 manufacturing facilities. Notwithstanding the
foregoing, if GSK’s request to inspect the QS-21 manufacturing facilities as contemplated hereunder conflicts with any Third Party rights to which Antigenics MA has Manufacture or supply obligations, the Parties will work together, in good
faith, to identify an appropriate resolution to the conflict. Further notwithstanding the foregoing, in the event that Antigenics MA has a Third Party Manufacture and supply QS-21 to Antigenics MA, for subsequent supply to GSK pursuant to this
Agreement, Antigenics MA shall [**] [**] with respect to [**]. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 20 

 Confidential 
  

 4.5 Exchange of information. Antigenics MA and GSK shall fully cooperate to achieve acceptance
of Antigenics MA facilities by Regulatory Authorities, and to exchange information about lots produced by the Parties in accordance with this Agreement, the Quality Agreement and the Manufacturing Technology Transfer Plan. 
 5. Consideration to Antigenics MA. 
 5.1 Upfront
Payment. As partial consideration for the Manufacturing Technology rights transferred to GSK pursuant to this Agreement, and Antigenics MA’s agreement to provide expertise in connection therewith in accordance with this Agreement, GSK shall
make a non-refundable, non-creditable upfront payment to Antigenics MA within [**] from execution of this Agreement in the amount of [**] dollars (US$[**]). 
 5.2 Milestone Payments. As further consideration for the Manufacturing Technology rights transferred to GSK pursuant to this Agreement, and Antigenics MA’s agreement to provide expertise in connection
therewith in accordance with this Agreement, GSK shall pay Antigenics MA the following milestone payments within [**] of achievement of the applicable milestone events: 
  

			
	 Milestone Event
	  	 Milestone
Payment

	 (a) Upon [**]
	  	US $[**]
	 (b) Upon [**]
	  	US $[**]

 5.3 Manufacturing Technology Transfer Royalty. As further consideration for the
Manufacturing Technology rights transferred to GSK pursuant to this Agreement, and Antigenics MA’s agreement to provide expertise in connection therewith in accordance with this Agreement, commencing with the First Commercial Sale of QS-21
Vaccines by GSK or its Affiliates or Third Party Sublicensees or distributors, GSK shall pay Antigenics MA a Manufacturing Technology transfer royalty (“Manufacturing Technology Transfer Royalty”) of [**] percent [**] of Net Sales
throughout the Territory. 
 This Manufacturing Technology Transfer Royalty obligation shall apply: (i) with respect to prophylactic QS-21 Vaccines for
ten (10) years after the First Commercial Sale of the first prophylactic QS-21 Vaccine in a Major Market Country (as defined below); and (ii) with respect to therapeutic QS-21 Vaccines for ten (10) years after the First Commercial
Sale of the first therapeutic QS-21 Vaccine in a Major Market Country. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 21 

 Confidential 
  

 In addition and notwithstanding the foregoing, in no event shall the foregoing Manufacturing Technology Transfer
Royalty obligation apply with respect to QS-21 Vaccines in the [**] for less than [**] years after the First Commercial Sale of the first prophylactic or first therapeutic [**]; and in no event shall the foregoing Manufacturing Technology Transfer
Royalty obligation apply with respect to QS-21 Vaccines in the [**] for less than [**] years after the First Commercial Sale of the first prophylactic or first therapeutic [**]. 
 As used herein, “Major Market Country” means the countries of the United States, France, Germany, Italy, the United Kingdom, Canada, Spain, Australia, Japan and, in the case of a Licensed Vaccine for
the Licensed Indication of [**]. 
 The foregoing Manufacturing Technology Transfer Royalty shall not be subject to any reductions. 
 5.4 QS-21 Supply Transfer Pricing. As consideration for Antigenics MA agreeing to supply GSK with QS-21 under this Agreement, GSK shall pay
Antigenics MA a transfer price of [**] percent ([**]%) of the Fully Burdened Costs for QS-21 delivered hereunder up to [**], and thereafter GSK shall pay Antigenics MA a transfer price of [**] percent ([**]%) of the Fully Burdened Costs for QS-21
delivered hereunder. Antigenics MA shall invoice GSK upon delivery to the common carrier and GSK shall pay Antigenics MA in U.S. dollars (USD) within [**] days of the invoice date unless rejected by GSK under Section 4.2 for each order of
QS-21.  
 5.5 Other Costs. GSK shall reimburse Antigenics MA for Other Costs in accordance with Section 2.3(e) hereof.

 5.6 GSK Audit Rights. At the request of GSK, upon at least [**] prior written notice to Antigenics MA and at the expense of GSK
(except as otherwise provided below), Antigenics MA shall permit an experienced, independent certified public accountant selected by GSK and reasonably acceptable to Antigenics MA to inspect, during regular business hours, any such records of
Antigenics MA for the then-preceding [**] solely to the extent necessary to verify Fully Burden Costs provided that such inspection shall not take place more often than once a year, and shall not cover such records for more than the preceding [**]
and shall not cover the same records more than once unless this is reasonably necessary for confirming the accuracy of existing records. Results of any such inspection shall be made available to both Parties. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 22 

 Confidential 
  

 6. Payments, Reports and Records. 
 6.1 First Commercial Sale. GSK shall notify Antigenics MA of the occurrence of the First Commercial Sale of each therapeutic QS-21 Vaccine and
each prophylactic QS-21 Vaccine in each country within [**] days of its occurrence. 
 6.2 Payments. Commencing with the First
Commercial Sale of the first QS-21 Vaccine in any country, GSK shall furnish to Antigenics MA a written report within [**] showing, on a country-by-country basis: (i) Gross Sales by GSK and its Affiliates and Third Party Sublicensees during the
reporting period; (ii) the Net Sales of all such QS-21 Vaccines sold, and qualifying discounts as described in Section 1.25, listed by category of deductions; (iii) the Manufacturing Technology Transfer Royalties payable in United
States dollars which shall have accrued hereunder in respect of such sales; (iv) withholding taxes, if any, required by law to be deducted in respect of such sales, as applicable; and (v) the exchange rates used in determining the amount
of United States dollars. All Manufacturing Technology Transfer Royalty payments shown to have accrued to Antigenics MA by each report provided for under this Section shall be due and payable on the date such report is due. If no payments are due
for any reporting period hereunder, GSK shall so report. All payments to Antigenics MA under this Agreement shall be made in United States dollars by check payable to “Antigenics Inc.” or, if requested by Antigenics MA, by wire transfer to
an account designated by Antigenics MA. 
 6.3 Withholding Taxes. All royalty payments are exclusive of all federal, state, local and
foreign taxes, levies, and assessments, duties, customs and similar charges. GSK shall be responsible for any and all such applicable charges incident to the payments to Antigenics MA under this Agreement, other than taxes on Antigenics MA’s
income. When Antigenics MA has the legal obligation to collect such taxes, the appropriate amount shall be paid by GSK (by adding such amount to the payment otherwise due to Antigenics MA), unless GSK provides Antigenics MA with a valid tax
exemption certificate authorized by the appropriate taxing authority. In the event that GSK is required by applicable law to make deductions or withholdings from payments to Antigenics MA hereunder, then GSK shall pay such additional amounts to
Antigenics MA as may be necessary to assure that the actual amount received by Antigenics MA after deduction or withholding shall equal the amount that would have been received if such deduction or withholding were not required. 
 6.4 Exchange Rates. If GSK (or its Affiliates or Third Party Sublicensees) receives revenues from the sale of QS-21 Vaccines in currency other
than United States dollars, revenues shall be converted to United States dollars at the conversion rate for foreign currency as published in the eastern edition of The Wall Street Journal published on the last Business Day of the applicable
calendar quarter. 
 6.5 GSK’s Recordkeeping and Inspection. After the date of First Commercial Sale of the first QS-21 Vaccine,
GSK shall keep, and shall cause its Affiliates and Third Party Sublicensees to keep, for at least [**], records of all sales of QS-21 Vaccines in sufficient detail to permit Antigenics MA to confirm (i) the accuracy of GSK’s Manufacturing
Technology Transfer Royalty payment calculations and (ii) the 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 23 

 Confidential 
  

 
Minimum Purchase Requirements. At the request of Antigenics MA, upon at least [**] prior written notice to GSK or its Affiliates or Third Party Sublicensees
and at the expense of Antigenics MA (except as otherwise provided below), GSK or its Affiliates or Third Party Sublicensees shall permit an experienced, independent certified public accountant selected by Antigenics MA and reasonably acceptable to
GSK or its Affiliates or Third Party Sublicensees to inspect, during regular business hours, any such records of GSK or its Affiliates or Third Party Sublicensees for the then-preceding [**] solely to the extent necessary to verify such calculations
provided that such inspection shall not take place more often than once a year, and shall not cover such records for more than the preceding [**]. Results of any such inspection shall be made available to both Parties. If such inspection reveals a
deficiency in the calculation of Manufacturing Technology Transfer Royalty payments or Minimum Purchase Requirements resulting in an underpayment to Antigenics MA by [**] or more, GSK shall pay all costs and expenses of such inspection. Any
deficiencies found shall be payable by GSK within [**] of receipt of invoice from Antigenics MA. If such inspection reveals an overpayment of Manufacturing Technology Transfer Royalty payments or Minimum Purchase Requirements resulting in an
underpayment to Antigenics MA by [**] or more, Antigenics MA shall refund to GSK any overpaid amounts within [**] after results of such inspection become available. 
 6.6 Interest on Late Payments. Any payment not timely made shall bear interest at a rate equal to [**]. 
 7.
Indemnification and Warranties. 
 7.1 Indemnification by GSK. GSK shall indemnify, defend, and hold harmless Antigenics MA and
its Affiliates and their respective directors, officers, employees, and agents, and its and their respective successors, heirs (current and former) and assigns (the “Antigenics MA Indemnitees”) from and against any and all loss,
liability, damage, cost, or expense (including reasonable legal fees and expenses of litigation) (collectively, “Liabilities”) suffered, incurred by, or imposed upon any such Antigenics MA Indemnitee, resulting from any Third Party
claims, demands, suits, actions, or judgments (collectively referred to hereafter as “Claims”) to the extent arising out of or resulting from (i) the development, pre-clinical or clinical testing, Manufacture, use, sale, offer for
sale, or importation of QS-21 Vaccines, including without limitation, the Manufacture of QS-21 for use therein, (ii) GSK’s breach of any representation, warranty or covenant of GSK hereunder, or (iii) the negligence or intentional
misconduct of GSK, in each case except to the extent such Liability is attributable (a) to the negligence or intentional misconduct of Antigenics MA, or (b) the failure of QS-21 delivered by Antigenics MA to meet the Specifications at the
time of shipment hereunder. 
 7.2 Indemnification by Antigenics MA. Antigenics MA shall indemnify, defend, and hold harmless GSK and
its Affiliates and its and their respective directors, officers, 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 24 

 Confidential 
  

 
employees, and agents, and its and their respective successors, heirs (current and former) and assigns (the “GSK Indemnitees”) from and
against any and all Liabilities suffered, incurred by, or imposed upon any such GSK Indemnitee, resulting from any Third Party Claims to the extent arising out of or resulting from (i) the failure of QS-21 to conform to the Specifications at
the time of shipment hereunder, or (ii) Antigenics MA’s breach of any representation, warranty or covenant hereunder, or (iii) the negligence or intentional misconduct of Antigenics MA, in each case except to the extent such Liability
is attributable to the negligence or intentional misconduct of GSK. 
 7.3 Conditions on Indemnification. Any Antigenics MA Indemnitee
or GSK Indemnitee (each an “Indemnitee”) intending to claim indemnification under this Article 7 shall promptly notify the other Party (the “Indemnifying Party”) of any Claim after the Indemnitee is aware thereof,
setting forth the nature of the Claim and the basis for indemnification hereunder, and the Indemnifying Party shall assume, at its sole cost and expense, the defense of the Claim with counsel mutually satisfactory to the Parties; provided,
however, that any Indemnitee shall have the right to retain its own counsel reasonably acceptable to the Indemnifying Party, at the expense of the Indemnifying Party, if representation of such Indemnitee by the counsel retained by the
Indemnifying Party would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other Party represented by such counsel. The Indemnitee shall cooperate fully with the Indemnifying Party in such
defense and will permit the Indemnifying Party to conduct and control such defense and disposition of such Claim (including all decisions relative to litigation, appeal and settlement), provided that (i) the Indemnifying Party agrees to keep
the Indemnitee informed of the progress in the defense and disposition of such Claim and to consult with the Indemnitee with regard to any proposed settlement, and (ii) the Indemnifying Party agrees not to enter into any settlement which would
have a material adverse effect on the other Party without prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. This indemnity agreement shall not apply to amounts paid in settlement of any Liability
if such settlement is effected without the consent of the Indemnifying Party, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnifying Party promptly after the Indemnitee receives notice of or otherwise
becomes aware of any such Claim, if prejudicial to its ability to defend such Claim, shall relieve the Indemnifying Party of any liability to the Indemnitee under this indemnity agreement. 
 7.4 Insurance. During the Term of this Agreement and for a period of [**] after the [**] of QS-21 Vaccines by GSK, its Affiliates or Third Party
Sublicensees or its or their distributors, GSK shall, at its discretion, either self-insure through a GlaxoSmithKline plc program, or obtain and carry, and shall cause its Sublicensees to obtain and carry, in full force and effect product liability
insurance in amounts which are reasonable and customary in the pharmaceutical industry for similar products. GSK shall provide Antigenics MA with appropriate certificates of insurance from time to time as requested by Antigenics MA unless GSK is
self-insured. During the Term of this Agreement and for a period of [**], after the [**] of QS-21 to GSK its Affiliates 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 25 

 Confidential 
  

 
or Third Party Sublicensees, Antigenics shall at its discretion, either self-insure through an Antigenics Inc. (parent corporation) program, or obtain and
carry, and shall cause its Sublicensees to obtain and carry, in full force and effect product liability insurance in amounts which are reasonable and customary in the pharmaceutical industry for similar products. Antigenics MA shall provide GSK with
appropriate certificates of insurance from time to time as requested by GSK unless Antigenics MA is self-insured. 
 7.5 Representation
and Warranties of GSK. GSK represents, warrants, and covenants to Antigenics MA as follows: 
 (a) GSK is a corporation
duly organized, validly existing and in good standing under the laws of Belgium. GSK has, and will have on all relevant dates, all requisite corporate power to own and operate its properties and assets and to carry on its business as presently being
conducted and as proposed to be conducted. GSK has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement, and to carry out and perform its obligations under the terms of this Agreement;

 (b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly
authorized by all appropriate GSK corporate action; 
 (c) the performance by GSK of any of the terms and conditions of this
Agreement on its part to be performed does not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party; and 
 (d) GSK will Manufacture, purchase and use, QS-21 and formulate, package and distribute the QS-21 Vaccines for marketing and sale in the
Territory solely in accordance with this Agreement and the License Agreement, and applicable laws, rules, regulations, and guidelines. 
 7.6
Representation and Warranties of Antigenics MA. Antigenics MA represents and warrants to GSK as follows: 
 (a)
Antigenics MA is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts. Antigenics MA has all requisite corporate power to own and operate its properties and assets and to carry on
its business as presently being conducted and as proposed to be conducted. Antigenics MA has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement; 
 (b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by
all appropriate Antigenics MA corporate action; 
  

 26 

 Confidential 
  

 (c) the performance by Antigenics MA of any of the terms and conditions of this
Agreement on its part to be performed does not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party; 
 (d) Antigenics MA shall Manufacture, or have Manufactured, QS-21 supplied to GSK hereunder in conformity with the Specifications and
applicable laws, rules, regulations, and guidelines; 
 (e) the Manufacturing Technology Package will contain all relevant
technological and regulatory information regarding QS-21 and QS-21 Manufacturing Process known to Antigenics MA that is necessary to manufacture QS-21 in accordance with the Specifications applicable as of the Effective Date; and 
 (f) to the best of Antigenics MA’s knowledge as of the Effective Date, there are no patents owned by Antigenics MA or its Affiliates,
other than as defined in Section 1.18, that would be infringed by GSK in practicing the right and licenses granted under this Agreement to Manufacture QS-21 in accordance with the Specifications applicable as of the Effective Date. 

7.7 LIMITATION OF LIABILITY. EXCEPT A) WITH RESPECT TO LIABILITY RELATING TO THIRD PARTY CLAIMS UNDER SECTIONS 7.1 OR 7.2, B) LIABILITY FOR
BREACH OF ARTICLE 9 AND C) CLAIMS FOR MISUSE, MISAPPROPRIATION OR INFRINGEMENT OF INTELLECTUAL PROPERTY, IT IS AGREED BY THE PARTIES THAT NEITHER PARTY NOR ITS AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY SPECIAL,
CONSEQUENTIAL, INDIRECT, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES (OTHER THAN REVENUES COMPRISING ROYALTIES OR OTHER PAYMENTS TO BE EARNED AND PAID TO A PARTY BY THE OTHER PARTY UNDER THIS AGREEMENT) OR PROFITS
RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR
LIKELIHOOD OF SAME. 
 7.8 DISCLAIMER OF WARRANTY. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN SECTION 7.6 HEREOF, ANTIGENICS MA MAKES
NO REPRESENTATIONS AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE QS-21 MANUFACTURED AND SUPPLIED HEREUNDER, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NON-INFRINGEMENT OF ANY THIRD PARTY PATENTS OR PROPRIETARY RIGHTS. ALL UNIFORM COMMERCIAL CODE WARRANTIES AND UNITED NATIONS CONVENTION ON THE INTERNATIONAL SALE OF GOODS WARRANTIES ARE EXPRESSLY DISCLAIMED BY ANTIGENICS MA. 
  

 27 

 Confidential 
  

 8. Term And Termination. 
 8.1 Term. Unless otherwise terminated pursuant to the terms hereof or by separate written agreement between the Parties, the term of this Agreement (the “Term”) shall begin on the Effective
Date and shall remain in full force and effect until expiration of the royalty obligations provided under Section 5.3 above. After that, GSK shall have a [**] license under the Manufacturing Technology to Manufacture QS-21 for use in any QS-21
Vaccines [**] under this Agreement, unless earlier terminated in accordance with Section 8.2 below. 
 8.2 Material Breach. If
either Party materially breaches any obligation, representation or warranty contained in this Agreement, the other Party shall be entitled to give to the Party in default written notice specifying the nature of the default and requiring it to cure
such default. If such default is not cured within [**] days for payments or [**] days after the receipt of such notice, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement and in
addition to any other remedies available to it by law or in equity, to terminate this Agreement effective upon written notice to the other Party. The right of a Party to terminate this Agreement, as hereinabove provided, shall not be affected in any
way by its waiver or failure to take action with respect to any previous default. For the purposes of this Section, a material breach of [**] by one Party shall be deemed a material breach and default of this Agreement by such Party, and shall
entitle the other Party to give notice of default under this Section. In addition, Antigenics MA shall have the right to terminate this Agreement and/or [**] immediately upon written notice to GSK in the event that GSK or its Affiliates challenge,
or direct or assist a Third Party to challenge, the validity, patentability or enforceability of, or otherwise oppose any, Licensed Patent Rights (as defined in the License Agreement) or the Manufacturing Technology. 
 8.3 Termination Or Continuation for Bankruptcy of Antigenics MA. 
 (a) GSK may terminate this Agreement if, at any time, Antigenics MA shall file in any court or agency pursuant to any statute or
regulation of (the United States or of) any (individual) state or (foreign) country, a petition in bankruptcy or insolvency or for reorganisation or for an arrangement or for the appointment of a receiver or trustee of the party or of its assets, or
if Antigenics MA proposes a written agreement of composition or extension of its debts, or if Antigenics MA shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed [**]
days after the filing thereof, or if Antigenics MA shall propose or be a party to any dissolution or liquidation, or if Antigenics MA shall make an assignment for the benefit of creditors. 
 (b) All rights and licenses granted under or pursuant to this Agreement by Antigenics MA are, and shall otherwise be deemed to be, for
purposes of Article 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Article 101 of the U.S. Bankruptcy Code so long as such rights do not conflict with any 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 28 

 Confidential 
  

 
of the terms of this Agreement. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against Antigenics MA under
the U.S. Bankruptcy Code, GSK shall be entitled to a complete duplicate of (or complete access to, as appropriate) the Manufacturing Technology and any such intellectual property and all embodiments of intellectual property consistent with Article
365(n) of the U.S. Bankruptcy Code, and same, if not already in its possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its written request therefore, unless Antigenics MA elects to
continue to perform all of its obligations under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of Antigenics MA upon written request therefore by GSK. All such
Manufacturing Technology and intellectual property so delivered shall remain subject to the use and confidentiality restrictions set forth in Article 9 of this Agreement and [**].
 8.4 Effects of Termination. 
 (a) Orders in Progress. In the event of expiration of this Agreement, Antigenics MA shall at GSK’s request or otherwise at its election, fill any purchase orders for QS-21 that were made by GSK and accepted by Antigenics MA
prior to such date, and GSK shall pay Antigenics MA for any QS-21 supplied by Antigenics MA hereunder. In addition, in the event of early termination of this Agreement, Antigenics MA retains the right but not the obligation to fill any purchase
orders for QS-21 that were made by GSK and accepted by Antigenics MA prior to such date, and GSK shall pay Antigenics MA for any QS-21 supplied by Antigenics MA hereunder. In either such an event, and in addition to the provisions set forth in
Section 8.4(b) and (c) below, the provisions of Sections 3.4(d) and (e) and 4.1 shall remain in full force and effect until the Parties have fulfilled their respective obligations with respect to such orders. 
 (b) Termination or expiration of this Agreement, for any reason, shall not deprive or relieve either Party hereto, of any right, remedy,
or obligation accrued hereunder prior to termination or expiration, and shall not effect any other rights accrued in any way under separate agreements between the Parties. 
 (c) The provisions of Articles 6 (with respect to outstanding payment obligations), 7, and 9, and Sections 2.6, 4.1 and 4.2 (with respect
to deliveries made prior to the date of expiration or termination or thereafter in accordance with Section 8.4(a) above) 4.3, 5.2, 5.3 (with respect to Net Sales of QS-21 Vaccines made prior to the date of expiration or termination), 5.4 (with
respect to deliveries made prior to the date of expiration or termination or thereafter in accordance with Section 8.4(a) above), 5.6, 8.1, 8.4, 10.1, 10.5, 10.6 (for so long as payment obligations survive the termination or expiration of this
Agreement), 10.8, 10.11, and 10.12 shall survive expiration or termination of this Agreement for any reason. In addition, (i) the provisions of Sections 2.5, 5.3 and Article 6 (with respect to payment obligations under Section 5.3) shall
survive termination of this Agreement for any reason, other than termination by Antigenics MA for GSK’s material breach, unless Antigenics MA elects otherwise in the case of such material breach. Furthermore, in the event this Agreement is
terminated by GSK under Section 8.2 for material breach of Antigenics MA (as agreed to by Antigenics 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 29 

 Confidential 
  

 
MA or finally resolved in accordance with the Dispute Resolution provisions of Section 10.1 of this Agreement), and, prior to such termination,
Antigenics MA incorporated a Manufacturing Improvement covered by a Valid Claim (as defined in the License Agreement) of a patent or patent application of GSK into the Manufacturing process of QS-21 at the request of GSK that results in a reduction
in the Fully Burdened Costs of greater than [**], then the [**] to [**] by [**] under Section [**] above shall (a) [**] be [**] a [**] at a [**], and the Parties shall [**] a [**] as [**] for [**] (which [**] shall [**] a [**] of the [**] in
the [**], and (b) [**] with respect to [**] not [**] by a [**]. 
 9. Confidentiality. 
 9.1 “Confidential Information” shall mean any technical, scientific or business information furnished by or on behalf of one Party or
its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”) in connection with this Agreement, the License Agreement or the Prior Agreement, or the activities contemplated
hereunder and thereunder, regardless of whether such information is specifically designated as confidential and regardless of whether such information is in oral, written, electronic or other form. The terms of this Agreement shall be considered
Confidential Information of both Parties, subject to the provisions of this Article 9 and Section 10.6. Confidential Information shall not include information that: 
 (a) is generally available in the public domain or thereafter becomes available to the public through no act of the Receiving Party; or

 (b) was independently known to the Receiving Party prior to receipt thereof or was discovered independently by an employee
of the Receiving Party who had no access to the information supplied by or on behalf of the Disclosing Party; or 
 (c) was
made available to the Receiving Party as a matter of lawful right by a Third Party who had no obligations of confidentiality to the Disclosing Party. 
 9.2 Obligations. The Receiving Party agrees that it shall not, without the prior written consent of the Disclosing Party, directly or indirectly: 
 (a) make any use, including but not limited to any research, commercial or potentially commercial use thereof, of any portion of the
Confidential Information of the Disclosing Party for purposes other than those set forth in this Agreement; or 
 (b)
duplicate, disseminate, disclose or transfer any portion of the Confidential Information to any person, except that the Receiving Party may disclose or permit the disclosure of Confidential Information to its Affiliates and sublicensees and its and
their respective directors, officers, employees, consultants, and advisors, and investors and potential investors in connection with a general financing transaction, and, (i) in the case of GSK, to Third Party (ies) (solely for the purpose of
[**]) as 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 30 

 Confidential 
  

 
may be useful or necessary to establish the [**] and (ii) in the case of Antigenics MA, to Third Party(ies) contract manufacturers as may be useful or
necessary to Manufacture for Antigenics MA as contemplated in this Agreement, in any case, who have an ethical or fiduciary duty to the Receiving Party or are otherwise obligated to maintain the confidential nature of such Confidential Information
and who need to know such Confidential Information for the purposes set forth in this Agreement, or for other legitimate business purposes; 
 Notwithstanding the above, the Receiving Party may disclose Confidential Information of the Disclosing Party when required by applicable laws or government rules or regulations (including without limitation, applicable securities
regulations), provided that to the extent reasonably possible, the Receiving Party provides reasonable prior written notice of such disclosure to the Disclosing Party and takes reasonable efforts to avoid and/or minimize the extent of disclosure.

 9.3 Upon expiration or termination of this Agreement and upon request of the Disclosing Party, all copies of any Disclosing Party’s
Confidential Information (other than the Manufacturing Technology in the case of expiration) shall be returned to the Disclosing Party, except that each Receiving Party may retain one (1) copy of the Confidential Information received hereunder
in the possession of its legal counsel, solely for monitoring its obligations under this Agreement. 
 9.4 No option, license, or conveyance
of such rights, express or implied, is granted to the Receiving Party in connection with any Confidential Information disclosed by the Disclosing Party, except for the express licenses granted in Article 2. If any such rights are to be granted to
the Receiving Party, such grant shall be expressly set forth in a separate written instrument. 
 10. Miscellaneous. 
 10.1 Dispute Resolution. Except for the right of any Party to apply to a court of competent jurisdiction for a temporary restraining order, a
preliminary injunction or other equitable relief to preserve the status quo or prevent irreparable harm, any dispute, other than disputes regarding the construction, validity or enforcement of patents, arising between the Parties relating to,
arising out of or in any way connected with this Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be resolved as follows:

 (a) If the dispute cannot be resolved by the Parties through their duly authorized representatives (or the Steering
Committee, if applicable) within [**], the Chief Executive Officer of GSK (or his designee) and the Chief Executive Office of Antigenics, Inc., a Delaware corporation, the parent corporation of Antigenics MA (or his designee) shall meet in person at
a mutually acceptable time and location or by means of telephone or video conference within [**] of the matter being referred to them. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 31 

 Confidential 
  

 (b) If the Chief Executive Officer of GSK (or his designee) and the Chief Executive
Officer of Antigenics, Inc. (or his designee) fail to first meet within [**] of the matter being referred to them, or if the dispute can not be resolved by the Chief Executive Officer of GSK (or his designee) and the Chief Executive Officer of
Antigenics, Inc. (or his designee) within [**] of the matter being referred to them, then either Party may bring such matter in a federal or state court in the State of Delaware to whose exclusive jurisdiction both Parties hereto consent.

 (c) Notwithstanding the foregoing, in the event there is a disagreement between the Parties as to whether [**] under
applicable [**] and [**] from [**] or other [**], such dispute shall be resolved by an independent panel of experts (the “[**] Panel”). The [**] Panel shall be composed of one (1) member if the Parties can agree on the sole member
within [**]. Otherwise, it shall be composed of one (1) member appointed by Antigenics MA, one (1) member appointed by GSK and a third member appointed by the agreement of first two (2) members. In order to be eligible for appointment
to the [**] Panel, a person must be independent in all respects from both Antigenics MA and GSK and have the [**]. The Parties shall identify their respective appointees within [**] following notice by one Party to the other of a [**] dispute. The
first two (2) members so appointed will have an additional [**] to choose the third member. Antigenics MA and GSK shall share equally any cost involved in the engagement and services of such third member. The Quality Panel shall determine
whether, in light of all circumstances, including without limitation, [**], the [**] the above referred [**]. Notwithstanding the foregoing, the Parties may, by agreement, identify a more specific or relevant [**] for the [**] Panel to consider in
resolving a particular dispute. The [**] Panel shall make its determination as soon as reasonably possible, but no later than [**] after referral of the dispute to the [**] Panel by the Parties. Decisions of the [**] Panel shall be made by [**] vote
of the members and shall be announced, with such reasoning as the [**] Panel, in its sole discretion, shall determine to be appropriate, in a document delivered on the same date to both Parties. 
 10.2 No Partnership. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, distributorship, agency,
employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 
 10.3 Assignments. This Agreement may not be assigned or otherwise transferred by either Party without the prior written consent of the other
Party, which consent shall not be unreasonably withheld or delayed; provided, however, that, GSK may, without such consent, assign this Agreement and any of its right or obligations hereunder to its Affiliates or in connection with the
transfer or sale of all or substantially all of the portion of its business to which this Agreement relates, or in the event of its merger or consolidation or reorganization or change in control; provided, further, that the assigning Party
shall deliver written notice of any such permitted assignment to the other 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 32 

 Confidential 
  

 
Party. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties and the name of a Party appearing
herein shall be deemed to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any attempted assignment not in accordance with this Section 10.3 shall be
void. 
 10.4 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such
other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.5 No Name or
Trademark Rights. Except as otherwise expressly provided herein, or expressly set forth in the License Agreement, no right, express or implied, is granted by this Agreement to use in any manner the names “Antigenics Inc.,”
“GlaxoSmithkline plc.” or any contraction thereof or any other trade name or trademark of Antigenics MA or GSK in connection with the performance of this Agreement. In addition, GSK agrees not use or apply for registration of any
trademarks, tradedresses or tradenames pertaining to QS-21 (as opposed to trademarks pertaining to QS-21 Vaccines) in the Territory without Antigenics MA’s prior consent, which consent shall not be unreasonably withheld where the use of such
trademarks, tradedresses or tradenames is required by applicable laws or regulations, provided that such use by GSK is consistent with both Party’s internal trademark policies. 
 10.6 Public Announcements. Press releases and public announcements regarding the subject matter of this Agreement shall be made in accordance with
the provisions of [**]. 
 10.7 Force Majeure. If any default or delay occurs which prevents or materially impairs a Party’s
performance and is due to a cause beyond the Party’s reasonable control, including but not limited to any act of god, flood, fire, explosion, earthquake, casualty, accident, war, revolution, terrorist acts, civil commotion, blockade or embargo,
injunction, law, proclamation, order, regulation or governmental demand, or acts, omissions or delays in acting by any Regulatory Authority, the affected Party promptly shall notify the other Party in writing of such cause and shall exercise
diligent efforts to resume performance under this Agreement as soon as possible. Neither Party shall be liable to the other Party for any loss or damage due to such cause. Neither Party may terminate this Agreement because of such default or delay,
unless such event continues unabated for a period of six (6) months, in which case the Party disadvantaged by such default or delay may, at its option, terminate this Agreement upon written notice to the other Party. 
 10.8 Entire Agreement of the Parties, Amendments. This Agreement, including the Exhibits attached hereto which are incorporated herein, and the
License Agreement, Quality Agreement, and Manufacturing Technology Transfer Plan, constitute and contain the entire understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings
and agreements, whether verbal or written, between the Parties respecting the subject matter hereof and thereof, including without limitation, the Prior Agreement. In the event of any inconsistency between this 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 33 

 Confidential 
  

 
Agreement and the Quality Agreement or the Manufacturing Technology Transfer Plan, the provisions of the Quality Agreement or the Manufacturing Technology
Transfer Plan shall prevail. In addition and for the avoidance of doubt, the Parties hereby agree that the Prior Agreement is terminated and fully superseded by this Agreement and the License Agreement as of the Effective Date of this Agreement.
Notwithstanding any provision to the contrary in the Prior Agreement, no provision contained in that agreement shall survive termination thereof. Notwithstanding the foregoing, each Party hereby agrees that all actions, suits, damages, or claims
which either of them may have against the other arising under the terms of the Prior Agreement, by reason of any breach of the Prior Agreement arising out of any act or failure to act prior to the Effective Date of this Agreement, is waived or
released hereby. No other waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each of the Parties. The foregoing provisions of this
Section 10.8 is subject to, and in no way diminishes, the rights of the Parties under Section [**] of the [**] with respect to the [**] (as defined in the [**]). 
 10.9 Severability. If any provision of this Agreement, or part thereof, is found by a proper authority to be unenforceable, that provision, or part thereof, shall be stricken and the remainder of this Agreement
will continue in full force and effect; provided, however, that the Parties shall renegotiate an acceptable replacement provision so as to accomplish, as nearly as possible, the original intent of the Parties. 
 10.10 Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of
the provisions of this Agreement. 
 10.11 Applicable Law; Governing Language. This Agreement shall be governed and construed in
accordance with the laws of the State of Delaware, without regard to conflicts of laws principles. This Agreement has been prepared in the English language and the English language shall control its interpretation. All consents, notices, reports and
other written documents to be delivered or provided by a Party under this Agreement shall be in the English language, and in the event of any conflict between the provisions of any document and the English language translation thereof, the terms of
the English language translation shall control. 
 10.12 Notices and Deliveries. Any notice or other communication required or
permitted hereunder shall be in writing and shall be deemed given (a) when delivered personally, (b) three (3) Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or
(c) one (1) day after deposit with a commercial express courier specifying next day delivery, with written verification or receipt, as follows: 
  

			
	If to Antigenics MA, to:	  	Antigenics Inc.
		  	3 Forbes Road
		  	Lexington MA 02421 U.S.A.
		  	Attention: Vice President, Business Development

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 34 

 Confidential 
  

			
	with copy to:	  	Antigenics Inc.
		  	3 Forbes Road
		  	Lexington MA 02421 U.S.A.
		  	Attention: Legal Department
		
	If to GSK, to:	  	GlaxoSmithKline Biologicals SA
		  	89 rue de l’Institut
		  	B-1330 Rixensart, BELGIUM
		  	Attention: President and General Manager
		
	with a copy to:	  	GlaxoSmithKline Biologicals SA
		  	89 rue de l’Institut
		  	B-1330 Rixensart, BELGIUM
		  	Attention: Legal Department

 However, all invoices shall be sent by Antigenics MA to GSK’s Licensing Manager, Account Department,
GlaxoSmithKline Biologicals SA, 89 rue de l’Institut, B-1330 Rixensart, Belgium or at such other address GSK may later designate in writing. 
 10.13 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 10.14 [**]. During the term of [**] under [**], [**] shall [**] and [**] to [**] to a [**] identified on Exhibit E (an “[**]”), the [**] to
[**] its [**] (outside the scope of the [**]), without [**] with [**]. Upon request [**] following [**] of such [**], the [**] the [**] and [**] under which [**] would [**], which, upon [**], shall [**] the [**] of the [**] and [**] of [**] to [**]
for [**]. In the event that the [**] have [**] such [**] and [**] within [**] after the [**] pursuant to which [**] would [**] shall be [**] or otherwise [**] to [**] the [**] to [**] the [**], without [**], and [**] any [**] that [**]. It is
understood that [**] only [**] hereunder [**] in such [**] with the [**], and that [**] is not [**] to [**] any [**] if [**]. Notwithstanding the foregoing, in no event shall the provisions of this Section apply with respect to (i) any [**]
relating to [**] or [**] of [**] or [**] or [**] of the [**] of [**] or [**], or (ii) 

  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 35 

 Confidential 
  

 
any [**]with any [**] other than with the [**]. 
 The remainder of this page is intentionally left blank. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 36 

 Confidential 
  

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be signed by their respective
corporate officers, duly authorized as of the day and year first above written. 
 Antigenics Inc., a Massachusetts corporation and wholly owned subsidiary
of Antigenics Inc., a Delaware corporation 
  

			
	By:	 	/s/ P. Thornton
		
	Name:	 	Peter Thornton
		
	Title:	 	Chief Financial Officer
	
	GlaxoSmithKline Biologicals SA
		
	By:	 	/s/ Jean Stephenne
		
	Name:	 	Jean Stephenne
		
	Title:	 	President, General Manager

  

 37 

 Confidential 
  

 Exhibit A 
 Specifications 
 [**] Specifications 
 QS-21 shall be produced and released according to Manufacturing methods and applicable [**]. 
 The release criteria and
specifications are set in the Quality Agreement. 
 [**] Specifications 
 QS-21 shall be produced and released in [**], in accordance with [**] methods of Manufacturing [**]. 
 The release criteria
and specifications are set in the current Quality Agreement. 
 The Parties agree that the [**] Specifications shall apply to Antigenics MA’s supply
obligations hereunder until such time as the Parties agree that the [**] Specifications apply in accordance with the Manufacturing Technology Transfer Plan. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit B 
 GSK’s QS-21 Forecasts 
 Q2 2006: [**] 
 Q3 2006: [**] 
 Q4 2006: [**] 
 Q1 2007: [**] 
 Q2 2007: [**] 
 Q3 2007: [**]

 Q4 2007: [**] 
 2008: [**] per [**] ([**] per year)

 2009: [**] per [**] ([**] per year) 
 2010: [**] per [**]
([**] per year) 
 2011: [**] per [**] ([**] per year) 
 2012-2014: [**] per [**] ([**] per year) 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit B-1 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit C 
 Manufacturing Capacity 
  

					
	 Quarter/year
	  	[**]	 	Antigenics MA
	 Q3/2006
	  	 [**]  
	 	[**]
	 Q4/2006
	  	[**]  	 	[**]
	 Q1/2007
	  	 [**] a
	 	[**]
	 Q2/2007
	  	[**] b	 	[**]
	 Q3/2007
	  	[**]b	 	[**]
	 Q4/2007
	  	 [**]b*
	 	[**]
	 Q1/2008
	  	[**]b*	 	[**]
	 Q2/2008
	  	[**]b*	 	  [**] c
[**]

  

	a	[**] can be [**] to [**] with an [**] and [**] from [**] of the [**]. 

  

	b	[**] can be [**] from [**] to [**] with an [**] and [**] from [**] of the [**]. 

  

	*	[**] with [**] to [**]. 

  

	c	[**] can be [**] with an [**] and [**] from [**] of the [**]. 

 For deliveries to be made from the last week of [**] onwards, the Manufacturing Capacity can be increased to [**], with [**] and [**] from [**]. In addition, for deliveries to be made from the last week of [**] onwards, Manufacturing
Capacity can be increased either (A) to [**] with an [**] and [**] from [**], or (B) to [**] with an [**] and [**], in each case, provided that in no event shall GSK’s requests for QS-21 [**]. 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit D 
 Estimated Fully Burdened Costs per MG – QS-21 – May 2005: 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 i 

 Confidential 
  

 Exhibit E 
 [**] 
  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version
of this exhibit has been filed separately with the Commission. 
 ii

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]